https://trial.medpath.com/news/ucb-s-fenfluramine-achieves-positive-phase-3-results-in-ultra-rare-cdkl5-deficiency-disorder 2025-06-27T08:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-s-fenfluramine-achieves-positive-phase-3-results-in-ultra-rare-cdkl5-deficiency-disorder 2025-06-27T08:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-amplifies-medtronic-recall-of-bravo-acid-reflux-test-capsules-after-33-serious-injuries 2025-06-27T06:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-amplifies-medtronic-recall-of-bravo-acid-reflux-test-capsules-after-33-serious-injuries 2025-06-27T06:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-accelerated-approval-for-edgewise-s-sevasemten-in-becker-muscular-dystrophy 2025-06-27T04:50:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-accelerated-approval-for-edgewise-s-sevasemten-in-becker-muscular-dystrophy 2025-06-27T04:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/zenocutuzumab-achieves-30-response-rate-in-nrg1-fusion-positive-solid-tumors-receives-fda-approval 2025-06-27T04:50:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenocutuzumab-achieves-30-response-rate-in-nrg1-fusion-positive-solid-tumors-receives-fda-approval 2025-06-27T04:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/orano-med-expands-texas-r-d-center-to-advance-lead-212-targeted-alpha-therapies 2025-06-27T03:13:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orano-med-expands-texas-r-d-center-to-advance-lead-212-targeted-alpha-therapies 2025-06-27T03:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-linked-to-increased-red-blood-cell-counts-but-no-thrombotic-risk-in-type-2-diabetes-patients 2025-06-27T03:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt2-inhibitors-linked-to-increased-red-blood-cell-counts-but-no-thrombotic-risk-in-type-2-diabetes-patients 2025-06-27T03:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-model-achieves-96-accuracy-in-predicting-breast-cancer-treatment-related-cardiac-events 2025-06-27T02:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-model-achieves-96-accuracy-in-predicting-breast-cancer-treatment-related-cardiac-events 2025-06-27T02:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/tilray-medical-publishes-pharmacokinetic-study-comparing-oral-and-oromucosal-cannabis-formulations 2025-06-27T00:52:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tilray-medical-publishes-pharmacokinetic-study-comparing-oral-and-oromucosal-cannabis-formulations 2025-06-27T00:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/eva-pharma-establishes-eighth-global-office-in-hangzhou-s-biopharma-town-to-advance-cell-and-gene-therapy-innovation 2025-06-27T00:52:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eva-pharma-establishes-eighth-global-office-in-hangzhou-s-biopharma-town-to-advance-cell-and-gene-therapy-innovation 2025-06-27T00:52:18+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-escalates-patent-defense-with-three-new-biosimilar-lawsuits-targeting-denosumab-competitors 2025-06-27T00:52:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-escalates-patent-defense-with-three-new-biosimilar-lawsuits-targeting-denosumab-competitors 2025-06-27T00:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-neopred-predicts-lung-cancer-treatment-response-before-surgery-using-dual-phase-ct-imaging 2025-06-27T00:51:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-neopred-predicts-lung-cancer-treatment-response-before-surgery-using-dual-phase-ct-imaging 2025-06-27T00:51:14+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-submits-first-clinical-trial-application-for-rna-editing-platform-with-ax-0810-targeting-cholestatic-liver-disease 2025-06-27T00:50:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proqr-submits-first-clinical-trial-application-for-rna-editing-platform-with-ax-0810-targeting-cholestatic-liver-disease 2025-06-27T00:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-sympatico-study-shows-promising-first-line-ibrutinib-venetoclax-combination-for-older-mcl-patients 2025-06-27T00:50:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-sympatico-study-shows-promising-first-line-ibrutinib-venetoclax-combination-for-older-mcl-patients 2025-06-27T00:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-european-patient-receives-breakthrough-treatment-for-ultra-rare-apds-immune-disorder 2025-06-27T00:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-european-patient-receives-breakthrough-treatment-for-ultra-rare-apds-immune-disorder 2025-06-27T00:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/modus-therapeutics-secures-sek-28-3-million-in-fully-subscribed-rights-issue-to-advance-sevuparin-development 2025-06-27T00:15:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modus-therapeutics-secures-sek-28-3-million-in-fully-subscribed-rights-issue-to-advance-sevuparin-development 2025-06-27T00:15:59+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-secures-4-4-million-in-funding-to-advance-clinical-trials-for-cancer-and-pain-therapeutics 2025-06-27T00:15:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artelo-biosciences-secures-4-4-million-in-funding-to-advance-clinical-trials-for-cancer-and-pain-therapeutics 2025-06-27T00:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-appoints-scott-madel-as-chief-commercial-officer-to-drive-infoods-ibs-test-commercialization 2025-06-27T00:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomerica-appoints-scott-madel-as-chief-commercial-officer-to-drive-infoods-ibs-test-commercialization 2025-06-27T00:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-courts-uphold-medicare-drug-price-negotiation-program-against-pharmaceutical-industry-challenges 2025-06-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-courts-uphold-medicare-drug-price-negotiation-program-against-pharmaceutical-industry-challenges 2025-06-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/budget-impact-analysis-shows-revumenib-cost-neutral-for-health-plans-despite-high-specialty-drug-costs 2025-06-26T23:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/budget-impact-analysis-shows-revumenib-cost-neutral-for-health-plans-despite-high-specialty-drug-costs 2025-06-26T23:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/prokaryotics-secures-global-rights-to-novel-gram-negative-antibiotic-potentiator-nab741 2025-06-26T22:14:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prokaryotics-secures-global-rights-to-novel-gram-negative-antibiotic-potentiator-nab741 2025-06-26T22:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-commits-eur129-million-to-expand-irish-operations-with-focus-on-biologics-manufacturing 2025-06-26T21:12:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-commits-eur129-million-to-expand-irish-operations-with-focus-on-biologics-manufacturing 2025-06-26T21:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/theracosbio-partners-with-publix-to-expand-access-to-low-cost-sglt2-inhibitor-brenzavvy-for-type-2-diabetes 2025-06-26T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theracosbio-partners-with-publix-to-expand-access-to-low-cost-sglt2-inhibitor-brenzavvy-for-type-2-diabetes 2025-06-26T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-names-bill-meury-as-new-ceo-replacing-11-year-veteran-herve-hoppenot 2025-06-26T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-names-bill-meury-as-new-ceo-replacing-11-year-veteran-herve-hoppenot 2025-06-26T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-launches-journavx-first-non-opioid-acute-pain-treatment-in-over-two-decades 2025-06-26T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-launches-journavx-first-non-opioid-acute-pain-treatment-in-over-two-decades 2025-06-26T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-siemens-healthineers-first-virtually-helium-free-1-5t-mri-scanner 2025-06-26T20:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-siemens-healthineers-first-virtually-helium-free-1-5t-mri-scanner 2025-06-26T20:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/ku-medical-center-receives-31-million-nih-grant-to-expand-pediatric-clinical-trial-access-in-underserved-areas 2025-06-26T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ku-medical-center-receives-31-million-nih-grant-to-expand-pediatric-clinical-trial-access-in-underserved-areas 2025-06-26T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/tfs-healthscience-demonstrates-specialized-capabilities-in-complex-ophthalmology-trials-for-geographic-atrophy-and-dry-eye-disease 2025-06-26T20:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tfs-healthscience-demonstrates-specialized-capabilities-in-complex-ophthalmology-trials-for-geographic-atrophy-and-dry-eye-disease 2025-06-26T20:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-appoints-than-powell-as-chief-business-officer-to-lead-alzheimer-s-and-hlhs-program-strategy 2025-06-26T20:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longeveron-appoints-than-powell-as-chief-business-officer-to-lead-alzheimer-s-and-hlhs-program-strategy 2025-06-26T20:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/angel-yeast-advances-biomanufacturing-with-new-biotechnology-park-set-for-september-launch 2025-06-26T18:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angel-yeast-advances-biomanufacturing-with-new-biotechnology-park-set-for-september-launch 2025-06-26T18:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/embolization-inc-receives-fda-clearance-for-novel-nonmetal-vascular-coil-device 2025-06-26T18:11:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/embolization-inc-receives-fda-clearance-for-novel-nonmetal-vascular-coil-device 2025-06-26T18:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/cellarity-initiates-phase-1-trial-of-cly-124-first-in-class-oral-therapy-for-sickle-cell-disease 2025-06-26T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellarity-initiates-phase-1-trial-of-cly-124-first-in-class-oral-therapy-for-sickle-cell-disease 2025-06-26T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-shares-plunge-60-despite-positive-mash-trial-results-as-fibrosis-endpoint-falls-short 2025-06-26T18:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altimmune-shares-plunge-60-despite-positive-mash-trial-results-as-fibrosis-endpoint-falls-short 2025-06-26T18:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/provectus-pv-10-immunotherapy-shows-promise-in-head-and-neck-cancer-through-novel-cell-death-mechanism 2025-06-26T17:01:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/provectus-pv-10-immunotherapy-shows-promise-in-head-and-neck-cancer-through-novel-cell-death-mechanism 2025-06-26T17:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-expands-public-coverage-of-xtandi-for-high-risk-prostate-cancer-patients 2025-06-26T16:55:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ontario-expands-public-coverage-of-xtandi-for-high-risk-prostate-cancer-patients 2025-06-26T16:55:02+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-successfully-transfers-lumevoq-manufacturing-to-catalent-for-lhon-gene-therapy 2025-06-26T16:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-biologics-successfully-transfers-lumevoq-manufacturing-to-catalent-for-lhon-gene-therapy 2025-06-26T16:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-shows-promise-for-early-detection-of-heart-transplant-rejection-could-replace-80-of-invasive-biopsies 2025-06-26T16:54:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-shows-promise-for-early-detection-of-heart-transplant-rejection-could-replace-80-of-invasive-biopsies 2025-06-26T16:54:47+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-once-daily-nebulized-lama-for-copd-triggering-7-5m-milestone-for-theravance 2025-06-26T16:52:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-once-daily-nebulized-lama-for-copd-triggering-7-5m-milestone-for-theravance 2025-06-26T16:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-s-certepetide-shows-promising-results-in-phase-2b-pancreatic-cancer-trial 2025-06-26T16:52:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-s-certepetide-shows-promising-results-in-phase-2b-pancreatic-cancer-trial 2025-06-26T16:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-scientists-develop-single-shot-malaria-vaccine-using-programmable-microcapsule-technology 2025-06-26T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-scientists-develop-single-shot-malaria-vaccine-using-programmable-microcapsule-technology 2025-06-26T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/alebund-s-ap301-meets-primary-endpoint-in-phase-3-trial-for-hyperphosphatemia-in-dialysis-patients 2025-06-26T16:18:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alebund-s-ap301-meets-primary-endpoint-in-phase-3-trial-for-hyperphosphatemia-in-dialysis-patients 2025-06-26T16:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/liposomal-lipid-nanoparticles-show-enhanced-extrahepatic-mrna-delivery-and-improved-stability 2025-06-26T16:17:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liposomal-lipid-nanoparticles-show-enhanced-extrahepatic-mrna-delivery-and-improved-stability 2025-06-26T16:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/plus-therapeutics-prepares-cnside-diagnostics-platform-for-u-s-commercial-launch-in-second-half-2025 2025-06-26T16:17:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plus-therapeutics-prepares-cnside-diagnostics-platform-for-u-s-commercial-launch-in-second-half-2025 2025-06-26T16:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/sysmex-america-secures-fda-clearance-for-cn-6000-automated-blood-coagulation-analyzer 2025-06-26T16:17:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sysmex-america-secures-fda-clearance-for-cn-6000-automated-blood-coagulation-analyzer 2025-06-26T16:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/portable-gene-therapy-device-could-revolutionize-on-demand-personalized-medicine-for-rare-diseases 2025-06-26T16:16:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portable-gene-therapy-device-could-revolutionize-on-demand-personalized-medicine-for-rare-diseases 2025-06-26T16:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/lipocine-initiates-phase-3-trial-for-oral-brexanolone-in-postpartum-depression 2025-06-26T16:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipocine-initiates-phase-3-trial-for-oral-brexanolone-in-postpartum-depression 2025-06-26T16:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/xeomin-receives-first-ever-approval-in-japan-for-chronic-sialorrhea-treatment 2025-06-26T16:15:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xeomin-receives-first-ever-approval-in-japan-for-chronic-sialorrhea-treatment 2025-06-26T16:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enhanced-labeling-for-endari-based-on-post-marketing-pharmacokinetic-data 2025-06-26T16:15:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-enhanced-labeling-for-endari-based-on-post-marketing-pharmacokinetic-data 2025-06-26T16:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/imcd-acquires-trichem-to-strengthen-pharmaceutical-supply-chain-in-india-s-generic-drug-market 2025-06-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imcd-acquires-trichem-to-strengthen-pharmaceutical-supply-chain-in-india-s-generic-drug-market 2025-06-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zyversa-therapeutics-initiates-phase-2a-trial-for-first-in-class-diabetic-kidney-disease-treatment-var-200 2025-06-26T15:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyversa-therapeutics-initiates-phase-2a-trial-for-first-in-class-diabetic-kidney-disease-treatment-var-200 2025-06-26T15:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/c7-neurotomy-combined-with-speech-therapy-shows-superior-results-for-chronic-post-stroke-aphasia 2025-06-26T14:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c7-neurotomy-combined-with-speech-therapy-shows-superior-results-for-chronic-post-stroke-aphasia 2025-06-26T14:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/profound-therapeutics-partners-with-novartis-in-775m-cardiovascular-drug-discovery-deal 2025-06-26T12:52:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profound-therapeutics-partners-with-novartis-in-775m-cardiovascular-drug-discovery-deal 2025-06-26T12:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-demonstrates-selumetinib-efficacy-in-adults-with-neurofibromatosis-type-1 2025-06-26T12:52:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-demonstrates-selumetinib-efficacy-in-adults-with-neurofibromatosis-type-1 2025-06-26T12:52:31+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-sells-ganaxolone-royalty-rights-to-immedica-pharma-for-7-million 2025-06-26T11:50:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-sells-ganaxolone-royalty-rights-to-immedica-pharma-for-7-million 2025-06-26T11:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/former-pfizer-cso-mikael-dolsten-joins-two-biotech-boards-advancing-gene-editing-and-mast-cell-therapeutics 2025-06-26T11:50:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-pfizer-cso-mikael-dolsten-joins-two-biotech-boards-advancing-gene-editing-and-mast-cell-therapeutics 2025-06-26T11:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-only-8-of-patients-continue-glp-1-obesity-treatment-after-three-years 2025-06-26T11:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-only-8-of-patients-continue-glp-1-obesity-treatment-after-three-years 2025-06-26T11:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/invetech-and-aicella-form-strategic-partnership-to-integrate-ai-into-cell-therapy-manufacturing 2025-06-26T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invetech-and-aicella-form-strategic-partnership-to-integrate-ai-into-cell-therapy-manufacturing 2025-06-26T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/kymera-therapeutics-raises-250-8-million-to-advance-targeted-protein-degradation-pipeline 2025-06-26T10:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kymera-therapeutics-raises-250-8-million-to-advance-targeted-protein-degradation-pipeline 2025-06-26T10:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-establishes-independent-drug-regulatory-authority-by-end-2026-ending-reliance-on-foreign-approvals 2025-06-26T09:11:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-establishes-independent-drug-regulatory-authority-by-end-2026-ending-reliance-on-foreign-approvals 2025-06-26T09:11:13+00:00 hourly 0.9 https://trial.medpath.com/news/teva-partners-with-formycon-to-commercialize-stelara-biosimilar-fymskina-in-germany 2025-06-26T09:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-partners-with-formycon-to-commercialize-stelara-biosimilar-fymskina-in-germany 2025-06-26T09:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/ambry-genetics-care-program-achieves-99-5-accuracy-in-hereditary-cancer-risk-assessment 2025-06-26T09:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ambry-genetics-care-program-achieves-99-5-accuracy-in-hereditary-cancer-risk-assessment 2025-06-26T09:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/2-million-donation-accelerates-car-t-cell-immunotherapy-trials-for-end-stage-cancer-patients-in-canada 2025-06-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2-million-donation-accelerates-car-t-cell-immunotherapy-trials-for-end-stage-cancer-patients-in-canada 2025-06-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lift-biosciences-expands-u-s-operations-with-new-houston-facility-to-advance-novel-neutrophil-immunotherapy 2025-06-26T07:12:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lift-biosciences-expands-u-s-operations-with-new-houston-facility-to-advance-novel-neutrophil-immunotherapy 2025-06-26T07:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/updated-covid-19-vaccines-show-strong-protection-against-severe-illness-in-comprehensive-cdc-study 2025-06-26T07:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-covid-19-vaccines-show-strong-protection-against-severe-illness-in-comprehensive-cdc-study 2025-06-26T07:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/bavarian-nordic-initiates-first-clinical-trials-of-mpox-vaccine-in-infants-and-pregnant-women 2025-06-26T07:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bavarian-nordic-initiates-first-clinical-trials-of-mpox-vaccine-in-infants-and-pregnant-women 2025-06-26T07:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/infliximab-biosimilar-adoption-in-pediatric-ibd-reaches-42-by-2023-reveals-regional-disparities 2025-06-26T05:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infliximab-biosimilar-adoption-in-pediatric-ibd-reaches-42-by-2023-reveals-regional-disparities 2025-06-26T05:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-acquires-phase-ii-ready-anti-vista-cancer-immunotherapy-hmbd-002-in-290m-deal 2025-06-26T04:11:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-acquires-phase-ii-ready-anti-vista-cancer-immunotherapy-hmbd-002-in-290m-deal 2025-06-26T04:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocity-s-sc0062-receives-second-breakthrough-therapy-designation-for-diabetic-kidney-disease-treatment 2025-06-26T04:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocity-s-sc0062-receives-second-breakthrough-therapy-designation-for-diabetic-kidney-disease-treatment 2025-06-26T04:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/neuren-pharmaceuticals-secures-us-patent-for-nnz-2591-in-pitt-hopkins-syndrome-treatment 2025-06-26T04:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuren-pharmaceuticals-secures-us-patent-for-nnz-2591-in-pitt-hopkins-syndrome-treatment 2025-06-26T04:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/vor-bio-secures-global-rights-to-telitacicept-in-4-billion-deal-with-remegen 2025-06-26T04:10:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vor-bio-secures-global-rights-to-telitacicept-in-4-billion-deal-with-remegen 2025-06-26T04:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-launches-world-s-first-clinical-trial-testing-thc-cbd-combination-for-canine-osteoarthritis 2025-06-26T04:10:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-launches-world-s-first-clinical-trial-testing-thc-cbd-combination-for-canine-osteoarthritis 2025-06-26T04:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/certify-raises-40m-series-b-to-transform-healthcare-provider-data-infrastructure 2025-06-26T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/certify-raises-40m-series-b-to-transform-healthcare-provider-data-infrastructure 2025-06-26T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-mycosis-fungoides-treatment-requires-strategic-sequencing-of-hdac-inhibitors-and-targeted-therapies 2025-06-26T03:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-mycosis-fungoides-treatment-requires-strategic-sequencing-of-hdac-inhibitors-and-targeted-therapies 2025-06-26T03:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/alafair-biosciences-initiates-multi-center-study-of-versawrap-hydrogel-device-for-achilles-tendon-repair 2025-06-26T03:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alafair-biosciences-initiates-multi-center-study-of-versawrap-hydrogel-device-for-achilles-tendon-repair 2025-06-26T03:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-s-reconstituted-vaccine-advisory-panel-votes-to-eliminate-thimerosal-from-all-flu-vaccines 2025-06-26T01:14:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-s-reconstituted-vaccine-advisory-panel-votes-to-eliminate-thimerosal-from-all-flu-vaccines 2025-06-26T01:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-initiates-comfort-toddlers-phase-3-study-for-viaskin-peanut-patch-in-young-children 2025-06-26T01:11:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dbv-technologies-initiates-comfort-toddlers-phase-3-study-for-viaskin-peanut-patch-in-young-children 2025-06-26T01:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-partners-with-csl-seqirus-for-exclusive-german-vaccine-distribution-deal 2025-06-26T01:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-partners-with-csl-seqirus-for-exclusive-german-vaccine-distribution-deal 2025-06-26T01:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-appoints-diede-van-den-ouden-as-new-ceo-to-advance-glioblastoma-drug-development 2025-06-26T00:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tme-pharma-appoints-diede-van-den-ouden-as-new-ceo-to-advance-glioblastoma-drug-development 2025-06-26T00:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/cellugy-secures-eur8-1-million-eu-funding-to-scale-microplastic-alternative-for-cosmetics-industry 2025-06-26T00:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellugy-secures-eur8-1-million-eu-funding-to-scale-microplastic-alternative-for-cosmetics-industry 2025-06-26T00:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/metabolics-pharma-s-ent-03-shows-promise-in-phase-1a-trial-for-obesity-and-type-2-diabetes 2025-06-25T23:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolics-pharma-s-ent-03-shows-promise-in-phase-1a-trial-for-obesity-and-type-2-diabetes 2025-06-25T23:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/ps7-5-million-longitude-prize-launches-to-accelerate-ai-driven-als-drug-discovery 2025-06-25T22:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ps7-5-million-longitude-prize-launches-to-accelerate-ai-driven-als-drug-discovery 2025-06-25T22:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/raybiotech-and-venebio-group-form-strategic-partnership-to-accelerate-drug-development-through-integrated-proteomics-and-regulatory-expertise 2025-06-25T22:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raybiotech-and-venebio-group-form-strategic-partnership-to-accelerate-drug-development-through-integrated-proteomics-and-regulatory-expertise 2025-06-25T22:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/minerva-biotechnologies-achieves-breakthrough-in-patient-derived-stem-cell-manufacturing-for-regenerative-medicine 2025-06-25T21:12:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minerva-biotechnologies-achieves-breakthrough-in-patient-derived-stem-cell-manufacturing-for-regenerative-medicine 2025-06-25T21:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/vetigenics-initiates-first-dual-immune-checkpoint-inhibitor-trial-in-dogs-with-solid-tumors 2025-06-25T21:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vetigenics-initiates-first-dual-immune-checkpoint-inhibitor-trial-in-dogs-with-solid-tumors 2025-06-25T21:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/jiuzhou-pharma-wins-china-patent-excellence-award-for-breakthrough-synthesis-technology 2025-06-25T21:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jiuzhou-pharma-wins-china-patent-excellence-award-for-breakthrough-synthesis-technology 2025-06-25T21:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-liquid-imatinib-formulation-addresses-critical-dosing-challenges-in-pediatric-cancer-and-dysphagia-patients 2025-06-25T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-liquid-imatinib-formulation-addresses-critical-dosing-challenges-in-pediatric-cancer-and-dysphagia-patients 2025-06-25T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/exousia-pro-files-patent-for-novel-exosome-loading-technology-targeting-multi-billion-dollar-therapeutic-markets 2025-06-25T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exousia-pro-files-patent-for-novel-exosome-loading-technology-targeting-multi-billion-dollar-therapeutic-markets 2025-06-25T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-ipsc-car-nk-cell-therapy-shows-promise-for-autoimmune-disease-treatment 2025-06-25T21:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-ipsc-car-nk-cell-therapy-shows-promise-for-autoimmune-disease-treatment 2025-06-25T21:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-receives-fda-clearance-for-incompass-total-ankle-system-integrating-dual-platform-technologies 2025-06-25T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stryker-receives-fda-clearance-for-incompass-total-ankle-system-integrating-dual-platform-technologies 2025-06-25T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/bryn-pharma-initiates-clinical-trial-for-dual-dose-epinephrine-nasal-spray-to-address-anaphylaxis-treatment-gaps 2025-06-25T21:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bryn-pharma-initiates-clinical-trial-for-dual-dose-epinephrine-nasal-spray-to-address-anaphylaxis-treatment-gaps 2025-06-25T21:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/daily-aspirin-reduces-colorectal-cancer-recurrence-by-55-in-patients-with-specific-genetic-mutations 2025-06-25T18:20:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daily-aspirin-reduces-colorectal-cancer-recurrence-by-55-in-patients-with-specific-genetic-mutations 2025-06-25T18:20:51+00:00 hourly 0.9 https://trial.medpath.com/news/recordati-secures-exclusive-european-rights-to-cardiovascular-drug-vazkepa-in-175-million-deal-with-amarin 2025-06-25T18:18:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recordati-secures-exclusive-european-rights-to-cardiovascular-drug-vazkepa-in-175-million-deal-with-amarin 2025-06-25T18:18:49+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-reports-positive-phase-1b-pet-trial-results-for-pipe-791-in-multiple-sclerosis-and-pulmonary-fibrosis 2025-06-25T18:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-therapeutics-reports-positive-phase-1b-pet-trial-results-for-pipe-791-in-multiple-sclerosis-and-pulmonary-fibrosis 2025-06-25T18:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-and-entera-bio-advance-first-in-class-oral-dual-glp-1-glucagon-tablet-for-obesity-treatment 2025-06-25T18:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opko-health-and-entera-bio-advance-first-in-class-oral-dual-glp-1-glucagon-tablet-for-obesity-treatment 2025-06-25T18:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-unveils-12-billion-pipeline-strategy-at-inaugural-r-d-day 2025-06-25T16:46:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-unveils-12-billion-pipeline-strategy-at-inaugural-r-d-day 2025-06-25T16:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/q32-bio-names-adrien-sipos-as-interim-cmo-to-lead-alopecia-areata-drug-development 2025-06-25T16:46:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/q32-bio-names-adrien-sipos-as-interim-cmo-to-lead-alopecia-areata-drug-development 2025-06-25T16:46:17+00:00 hourly 0.9 https://trial.medpath.com/news/arbutus-reacquires-global-rights-to-hepatitis-b-rnai-therapy-after-achieving-functional-cure-in-eight-patients 2025-06-25T16:44:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arbutus-reacquires-global-rights-to-hepatitis-b-rnai-therapy-after-achieving-functional-cure-in-eight-patients 2025-06-25T16:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/dicot-pharma-completes-enrollment-in-phase-2a-erectile-dysfunction-trial-results-expected-by-november-2025 2025-06-25T16:35:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dicot-pharma-completes-enrollment-in-phase-2a-erectile-dysfunction-trial-results-expected-by-november-2025 2025-06-25T16:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/assembly-biosciences-abi-4334-shows-potent-antiviral-activity-in-phase-1b-chronic-hepatitis-b-trial 2025-06-25T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/assembly-biosciences-abi-4334-shows-potent-antiviral-activity-in-phase-1b-chronic-hepatitis-b-trial 2025-06-25T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/mira-pharmaceuticals-unveils-preclinical-data-for-skny-1-targeting-obesity-and-smoking-cessation-without-cns-side-effects 2025-06-25T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mira-pharmaceuticals-unveils-preclinical-data-for-skny-1-targeting-obesity-and-smoking-cessation-without-cns-side-effects 2025-06-25T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-partners-with-sino-universal-pharmaceuticals-to-commercialize-tiotropium-dpi-for-copd-treatment-in-china 2025-06-25T16:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-partners-with-sino-universal-pharmaceuticals-to-commercialize-tiotropium-dpi-for-copd-treatment-in-china 2025-06-25T16:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/evaxion-launches-ai-powered-vaccine-program-against-group-a-streptococcus 2025-06-25T16:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaxion-launches-ai-powered-vaccine-program-against-group-a-streptococcus 2025-06-25T16:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-detalimogene-for-high-risk-bladder-cancer 2025-06-25T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-detalimogene-for-high-risk-bladder-cancer 2025-06-25T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/angel-pharmaceuticals-receives-china-ind-approval-for-soquelitinib-atopic-dermatitis-trial 2025-06-25T16:30:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angel-pharmaceuticals-receives-china-ind-approval-for-soquelitinib-atopic-dermatitis-trial 2025-06-25T16:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-kymera-s-next-generation-irak4-degrader-kt-485-to-clinical-testing 2025-06-25T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-advances-kymera-s-next-generation-irak4-degrader-kt-485-to-clinical-testing 2025-06-25T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-and-kymera-partner-on-novel-cdk2-molecular-glue-degrader-for-cancer-treatment 2025-06-25T16:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-and-kymera-partner-on-novel-cdk2-molecular-glue-degrader-for-cancer-treatment 2025-06-25T16:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-initiates-phase-3-trial-for-bat8006-adc-in-platinum-resistant-ovarian-cancer 2025-06-25T16:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-thera-solutions-initiates-phase-3-trial-for-bat8006-adc-in-platinum-resistant-ovarian-cancer 2025-06-25T16:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/hamlet-biopharma-receives-fda-clearance-for-phase-iii-bladder-cancer-trial-following-successful-regulatory-meeting 2025-06-25T16:29:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hamlet-biopharma-receives-fda-clearance-for-phase-iii-bladder-cancer-trial-following-successful-regulatory-meeting 2025-06-25T16:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/fraunhofer-researchers-develop-breakthrough-method-to-measure-lung-drug-levels-through-exhaled-breath-particles 2025-06-25T16:28:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fraunhofer-researchers-develop-breakthrough-method-to-measure-lung-drug-levels-through-exhaled-breath-particles 2025-06-25T16:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/femasys-receives-world-s-first-regulatory-approval-for-non-surgical-permanent-birth-control-system-in-europe 2025-06-25T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/femasys-receives-world-s-first-regulatory-approval-for-non-surgical-permanent-birth-control-system-in-europe 2025-06-25T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/minovia-therapeutics-announces-180m-spac-merger-to-advance-first-in-class-mitochondrial-therapy-platform 2025-06-25T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minovia-therapeutics-announces-180m-spac-merger-to-advance-first-in-class-mitochondrial-therapy-platform 2025-06-25T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-and-silo-pharma-form-joint-venture-to-develop-va-licensed-gdnf-based-obesity-treatment 2025-06-25T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-and-silo-pharma-form-joint-venture-to-develop-va-licensed-gdnf-based-obesity-treatment 2025-06-25T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/oral-sulopenem-shows-non-inferiority-to-standard-care-in-phase-3-trial-for-uncomplicated-utis 2025-06-25T16:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-sulopenem-shows-non-inferiority-to-standard-care-in-phase-3-trial-for-uncomplicated-utis 2025-06-25T16:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/breye-therapeutics-completes-phase-1b-trial-of-oral-danegaptide-for-early-stage-diabetic-retinopathy 2025-06-25T16:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breye-therapeutics-completes-phase-1b-trial-of-oral-danegaptide-for-early-stage-diabetic-retinopathy 2025-06-25T16:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/empatica-launches-world-s-smallest-clinical-trial-wearable-device-for-digital-biomarker-collection 2025-06-25T16:14:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empatica-launches-world-s-smallest-clinical-trial-wearable-device-for-digital-biomarker-collection 2025-06-25T16:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/botulinum-toxin-combination-therapy-reduces-salivary-gland-toxicity-in-psma-radioligand-treatment 2025-06-25T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/botulinum-toxin-combination-therapy-reduces-salivary-gland-toxicity-in-psma-radioligand-treatment 2025-06-25T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/plus-therapeutics-restructures-15-million-equity-financing-to-eliminate-potential-1-5-billion-share-dilution 2025-06-25T14:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plus-therapeutics-restructures-15-million-equity-financing-to-eliminate-potential-1-5-billion-share-dilution 2025-06-25T14:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/qbiotics-tigilanol-tiglate-achieves-80-response-rate-in-soft-tissue-sarcoma-phase-iia-trial 2025-06-25T12:52:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qbiotics-tigilanol-tiglate-achieves-80-response-rate-in-soft-tissue-sarcoma-phase-iia-trial 2025-06-25T12:52:57+00:00 hourly 0.9 https://trial.medpath.com/news/tgfb2-gene-methylation-identified-as-positive-prognostic-biomarker-for-pancreatic-cancer 2025-06-25T12:51:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tgfb2-gene-methylation-identified-as-positive-prognostic-biomarker-for-pancreatic-cancer 2025-06-25T12:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-advances-salanersen-to-phase-3-studies-for-spinal-muscular-atrophy-after-promising-results 2025-06-25T12:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-advances-salanersen-to-phase-3-studies-for-spinal-muscular-atrophy-after-promising-results 2025-06-25T12:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/metastx-receives-nci-grant-to-develop-ai-powered-diagnostic-for-metastatic-prostate-cancer-prediction 2025-06-25T12:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metastx-receives-nci-grant-to-develop-ai-powered-diagnostic-for-metastatic-prostate-cancer-prediction 2025-06-25T12:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/adipose-derived-stem-cell-therapy-achieves-100-hair-regrowth-in-male-mice-for-androgenetic-alopecia 2025-06-25T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adipose-derived-stem-cell-therapy-achieves-100-hair-regrowth-in-male-mice-for-androgenetic-alopecia 2025-06-25T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-initiates-intradermal-dosing-in-phase-2-melanoma-trial-reports-strong-early-efficacy-data 2025-06-25T08:51:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scancell-initiates-intradermal-dosing-in-phase-2-melanoma-trial-reports-strong-early-efficacy-data 2025-06-25T08:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-european-partner-withdraws-melanoma-therapy-application-from-ema-due-to-data-delays 2025-06-25T08:51:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-european-partner-withdraws-melanoma-therapy-application-from-ema-due-to-data-delays 2025-06-25T08:51:28+00:00 hourly 0.9 https://trial.medpath.com/news/valorum-biologics-secures-exclusive-rights-to-commercialize-formycon-s-eylea-biosimilar-in-north-america 2025-06-25T08:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valorum-biologics-secures-exclusive-rights-to-commercialize-formycon-s-eylea-biosimilar-in-north-america 2025-06-25T08:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-tumor-dna-testing-transforms-breast-cancer-monitoring-and-treatment-selection 2025-06-25T08:49:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circulating-tumor-dna-testing-transforms-breast-cancer-monitoring-and-treatment-selection 2025-06-25T08:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-launches-phase-ii-trials-of-nemolizumab-for-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin 2025-06-25T08:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galderma-launches-phase-ii-trials-of-nemolizumab-for-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin 2025-06-25T08:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/lts-and-nualtis-form-strategic-partnership-to-scale-oral-thin-film-drug-delivery-manufacturing 2025-06-25T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lts-and-nualtis-form-strategic-partnership-to-scale-oral-thin-film-drug-delivery-manufacturing 2025-06-25T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-joins-nurture-aki-consortium-to-advance-multi-omics-research-for-acute-kidney-injury-treatment 2025-06-25T07:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-joins-nurture-aki-consortium-to-advance-multi-omics-research-for-acute-kidney-injury-treatment 2025-06-25T07:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/vcu-researchers-develop-fusion-superkine-therapy-for-glioblastoma-with-novel-blood-brain-barrier-delivery-system 2025-06-25T06:11:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcu-researchers-develop-fusion-superkine-therapy-for-glioblastoma-with-novel-blood-brain-barrier-delivery-system 2025-06-25T06:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/civicascript-launches-low-cost-generic-dimethyl-fumarate-for-multiple-sclerosis-treatment 2025-06-25T06:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/civicascript-launches-low-cost-generic-dimethyl-fumarate-for-multiple-sclerosis-treatment 2025-06-25T06:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-advances-second-generation-cd47-inhibitor-iba101-toward-2027-clinical-trials 2025-06-25T06:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liminatus-pharma-advances-second-generation-cd47-inhibitor-iba101-toward-2027-clinical-trials 2025-06-25T06:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/clinicians-develop-new-monitoring-strategies-for-hypercortisolism-medical-management 2025-06-25T05:11:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinicians-develop-new-monitoring-strategies-for-hypercortisolism-medical-management 2025-06-25T05:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/zetroz-systems-sam-r-2-0-wearable-ultrasound-device-receives-arthritis-foundation-s-ease-of-use-certification 2025-06-25T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zetroz-systems-sam-r-2-0-wearable-ultrasound-device-receives-arthritis-foundation-s-ease-of-use-certification 2025-06-25T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/extended-imatinib-therapy-shows-promise-in-high-risk-gist-patients-as-novel-agents-enter-clinical-development 2025-06-25T03:14:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-imatinib-therapy-shows-promise-in-high-risk-gist-patients-as-novel-agents-enter-clinical-development 2025-06-25T03:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/bracelet-1-trial-shows-promise-for-oncolytic-virus-pelareorep-in-hr-breast-cancer 2025-06-25T02:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bracelet-1-trial-shows-promise-for-oncolytic-virus-pelareorep-in-hr-breast-cancer 2025-06-25T02:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/cue-biopharma-receives-positive-fda-feedback-for-cue-401-autoimmune-therapy-advances-toward-ind-filing 2025-06-25T01:13:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cue-biopharma-receives-positive-fda-feedback-for-cue-401-autoimmune-therapy-advances-toward-ind-filing 2025-06-25T01:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-delivers-first-brain-infused-gene-therapy-for-rare-aadc-deficiency-showing-promising-results-in-three-year-old-patient 2025-06-25T01:12:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-delivers-first-brain-infused-gene-therapy-for-rare-aadc-deficiency-showing-promising-results-in-three-year-old-patient 2025-06-25T01:12:47+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-olomorasib-receives-fda-orphan-drug-designation-for-kras-g12c-mutated-nsclc-treatment 2025-06-25T01:11:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-olomorasib-receives-fda-orphan-drug-designation-for-kras-g12c-mutated-nsclc-treatment 2025-06-25T01:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/trem2-emerges-as-dual-regulator-of-lipid-metabolism-and-immune-response-in-mash 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trem2-emerges-as-dual-regulator-of-lipid-metabolism-and-immune-response-in-mash 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/guselkumab-demonstrates-high-efficacy-for-psoriasis-treatment-across-all-skin-tones-in-landmark-visible-trial 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guselkumab-demonstrates-high-efficacy-for-psoriasis-treatment-across-all-skin-tones-in-landmark-visible-trial 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-secures-50-million-funding-following-yutrepia-commercial-launch-and-legal-victory 2025-06-24T22:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquidia-secures-50-million-funding-following-yutrepia-commercial-launch-and-legal-victory 2025-06-24T22:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/fortrea-and-emery-pharma-partner-to-enable-fda-compliant-rifampin-use-in-drug-drug-interaction-studies 2025-06-24T22:15:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fortrea-and-emery-pharma-partner-to-enable-fda-compliant-rifampin-use-in-drug-drug-interaction-studies 2025-06-24T22:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/pathpresenter-receives-fda-510-k-clearance-for-digital-pathology-clinical-viewer 2025-06-24T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathpresenter-receives-fda-510-k-clearance-for-digital-pathology-clinical-viewer 2025-06-24T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/cigna-sues-bristol-myers-squibb-over-alleged-monopoly-practices-for-cancer-drug-pomalyst 2025-06-24T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cigna-sues-bristol-myers-squibb-over-alleged-monopoly-practices-for-cancer-drug-pomalyst 2025-06-24T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-receives-who-approval-for-offshore-manufacturing-of-hiv-rapid-test 2025-06-24T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-receives-who-approval-for-offshore-manufacturing-of-hiv-rapid-test 2025-06-24T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-olanzapine-significantly-reduces-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-patients 2025-06-24T20:17:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-olanzapine-significantly-reduces-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-patients 2025-06-24T20:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/curiteva-receives-fda-510-k-clearance-for-first-3d-printed-peek-standalone-spinal-implant 2025-06-24T20:16:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curiteva-receives-fda-510-k-clearance-for-first-3d-printed-peek-standalone-spinal-implant 2025-06-24T20:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/breckenridge-pharmaceutical-receives-fda-approval-for-generic-dehydrated-alcohol-injection-for-hypertrophic-obstructive-cardiomyopathy 2025-06-24T20:15:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breckenridge-pharmaceutical-receives-fda-approval-for-generic-dehydrated-alcohol-injection-for-hypertrophic-obstructive-cardiomyopathy 2025-06-24T20:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/duvelisib-romidepsin-combination-shows-61-response-rate-in-relapsed-t-cell-lymphomas 2025-06-24T20:15:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duvelisib-romidepsin-combination-shows-61-response-rate-in-relapsed-t-cell-lymphomas 2025-06-24T20:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-promise-for-type-1-diabetes-in-off-label-use-study 2025-06-24T20:11:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-shows-promise-for-type-1-diabetes-in-off-label-use-study 2025-06-24T20:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/forsight-robotics-raises-125m-series-b-to-advance-oryom-robotic-eye-surgery-platform 2025-06-24T18:51:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forsight-robotics-raises-125m-series-b-to-advance-oryom-robotic-eye-surgery-platform 2025-06-24T18:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/abridge-secures-300m-series-e-funding-reaches-5-3b-valuation-for-ai-clinical-documentation-platform 2025-06-24T18:50:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abridge-secures-300m-series-e-funding-reaches-5-3b-valuation-for-ai-clinical-documentation-platform 2025-06-24T18:50:59+00:00 hourly 0.9 https://trial.medpath.com/news/inventprise-s-novel-covid-19-conjugate-vaccine-shows-broad-protection-against-multiple-variants-in-preclinical-study 2025-06-24T18:09:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventprise-s-novel-covid-19-conjugate-vaccine-shows-broad-protection-against-multiple-variants-in-preclinical-study 2025-06-24T18:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-pharmaceuticals-appoints-darren-cline-as-chief-commercial-officer-ahead-of-azetukalner-phase-3-data 2025-06-24T18:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xenon-pharmaceuticals-appoints-darren-cline-as-chief-commercial-officer-ahead-of-azetukalner-phase-3-data 2025-06-24T18:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-partners-with-malaysia-s-national-cancer-society-to-launch-biosimilar-access-program 2025-06-24T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-partners-with-malaysia-s-national-cancer-society-to-launch-biosimilar-access-program 2025-06-24T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/starton-therapeutics-partners-with-bend-bioscience-to-develop-oral-sustained-release-lenalidomide-for-multiple-myeloma 2025-06-24T17:15:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/starton-therapeutics-partners-with-bend-bioscience-to-develop-oral-sustained-release-lenalidomide-for-multiple-myeloma 2025-06-24T17:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/nct-ucc-dresden-launches-phase-2-trial-of-personalized-mrna-vaccine-for-pancreatic-cancer 2025-06-24T17:14:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nct-ucc-dresden-launches-phase-2-trial-of-personalized-mrna-vaccine-for-pancreatic-cancer 2025-06-24T17:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/priothera-secures-eur1-7-million-government-funding-to-enhance-car-t-cell-therapy-with-novel-s1p-receptor-modulator 2025-06-24T17:12:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priothera-secures-eur1-7-million-government-funding-to-enhance-car-t-cell-therapy-with-novel-s1p-receptor-modulator 2025-06-24T17:12:44+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-faces-patent-challenges-for-diabetes-drug-as-sandoz-seeks-revocation 2025-06-24T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-faces-patent-challenges-for-diabetes-drug-as-sandoz-seeks-revocation 2025-06-24T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/vector-biomed-partners-with-indian-cancer-hospital-to-deliver-affordable-car-t-therapy-to-rural-populations 2025-06-24T17:12:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vector-biomed-partners-with-indian-cancer-hospital-to-deliver-affordable-car-t-therapy-to-rural-populations 2025-06-24T17:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-submits-phase-1b-protocol-for-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-06-24T17:12:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-submits-phase-1b-protocol-for-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-06-24T17:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-hu6-demonstrates-significant-liver-fat-reduction-in-phase-2-mash-trial 2025-06-24T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rivus-pharmaceuticals-hu6-demonstrates-significant-liver-fat-reduction-in-phase-2-mash-trial 2025-06-24T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-roctavian-gene-therapy-shows-sustained-efficacy-after-five-years-in-severe-hemophilia-a 2025-06-24T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-s-roctavian-gene-therapy-shows-sustained-efficacy-after-five-years-in-severe-hemophilia-a 2025-06-24T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/favipiravir-shows-promise-against-deadly-chandipura-virus-in-preclinical-studies 2025-06-24T17:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/favipiravir-shows-promise-against-deadly-chandipura-virus-in-preclinical-studies 2025-06-24T17:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/enhanced-genomics-partners-with-alborada-institute-to-accelerate-alzheimer-s-drug-discovery-using-3d-multi-omics-platform 2025-06-24T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhanced-genomics-partners-with-alborada-institute-to-accelerate-alzheimer-s-drug-discovery-using-3d-multi-omics-platform 2025-06-24T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/mindrank-s-ai-designed-oral-glp-1-drug-achieves-10-3-weight-loss-in-phase-2b-trial 2025-06-24T16:24:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindrank-s-ai-designed-oral-glp-1-drug-achieves-10-3-weight-loss-in-phase-2b-trial 2025-06-24T16:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/neuron23-secures-96-5m-series-d-funding-as-first-patient-dosed-in-phase-2-parkinson-s-disease-trial 2025-06-24T16:23:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuron23-secures-96-5m-series-d-funding-as-first-patient-dosed-in-phase-2-parkinson-s-disease-trial 2025-06-24T16:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-expands-scientific-advisory-board-with-hcc-experts-as-phase-2-trial-approaches 2025-06-24T16:17:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-expands-scientific-advisory-board-with-hcc-experts-as-phase-2-trial-approaches 2025-06-24T16:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/cytodyn-initiates-phase-ii-trial-of-leronlimab-in-relapsed-refractory-colorectal-cancer 2025-06-24T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytodyn-initiates-phase-ii-trial-of-leronlimab-in-relapsed-refractory-colorectal-cancer 2025-06-24T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-s-inm-901-shows-significant-anti-inflammatory-activity-in-alzheimer-s-disease-preclinical-study 2025-06-24T16:15:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmed-s-inm-901-shows-significant-anti-inflammatory-activity-in-alzheimer-s-disease-preclinical-study 2025-06-24T16:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/stuart-therapeutics-reports-mixed-phase-iii-results-for-st-100-dry-eye-treatment 2025-06-24T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stuart-therapeutics-reports-mixed-phase-iii-results-for-st-100-dry-eye-treatment 2025-06-24T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/smart-soft-healthcare-s-columbo-ai-spine-assistant-receives-fda-clearance-for-enhanced-scoliosis-and-fracture-detection 2025-06-24T16:14:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-soft-healthcare-s-columbo-ai-spine-assistant-receives-fda-clearance-for-enhanced-scoliosis-and-fracture-detection 2025-06-24T16:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/jb-chemicals-secures-fda-approval-for-generic-amitriptyline-depression-treatment 2025-06-24T16:14:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jb-chemicals-secures-fda-approval-for-generic-amitriptyline-depression-treatment 2025-06-24T16:14:20+00:00 hourly 0.9 https://trial.medpath.com/news/kif18a-emerges-as-promising-cancer-target-with-multiple-therapies-advancing-through-clinical-trials 2025-06-24T16:14:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kif18a-emerges-as-promising-cancer-target-with-multiple-therapies-advancing-through-clinical-trials 2025-06-24T16:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-bioengineered-external-liver-assist-device-treats-patient-in-groundbreaking-clinical-trial 2025-06-24T16:14:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-bioengineered-external-liver-assist-device-treats-patient-in-groundbreaking-clinical-trial 2025-06-24T16:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-initiates-phase-3-trial-of-kb803-gene-therapy-for-corneal-complications-in-dystrophic-epidermolysis-bullosa 2025-06-24T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/krystal-biotech-initiates-phase-3-trial-of-kb803-gene-therapy-for-corneal-complications-in-dystrophic-epidermolysis-bullosa 2025-06-24T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/supercede-therapeutics-reports-promising-preclinical-data-for-novel-oral-obesity-treatment-targeting-actrii-pathway 2025-06-24T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supercede-therapeutics-reports-promising-preclinical-data-for-novel-oral-obesity-treatment-targeting-actrii-pathway 2025-06-24T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/schott-pharma-commits-eur100-million-to-expand-ready-to-use-sterile-cartridge-manufacturing 2025-06-24T13:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schott-pharma-commits-eur100-million-to-expand-ready-to-use-sterile-cartridge-manufacturing 2025-06-24T13:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/imdx-digital-pcr-platform-shows-equivalent-performance-to-ngs-in-kidney-transplant-rejection-testing 2025-06-24T13:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imdx-digital-pcr-platform-shows-equivalent-performance-to-ngs-in-kidney-transplant-rejection-testing 2025-06-24T13:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-partners-with-usp-to-enhance-quality-standards-for-monoclonal-antibody-and-gene-therapy-development 2025-06-24T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-techne-partners-with-usp-to-enhance-quality-standards-for-monoclonal-antibody-and-gene-therapy-development 2025-06-24T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/outsee-secures-ps1-8m-seed-funding-to-advance-ai-powered-genomics-platform-for-drug-discovery 2025-06-24T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outsee-secures-ps1-8m-seed-funding-to-advance-ai-powered-genomics-platform-for-drug-discovery 2025-06-24T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/sterotherapeutics-doses-first-patient-in-phase-2-trial-of-st-002-for-cushing-s-syndrome 2025-06-24T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sterotherapeutics-doses-first-patient-in-phase-2-trial-of-st-002-for-cushing-s-syndrome 2025-06-24T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-extends-16-year-research-partnership-with-tsinghua-university-for-three-more-years 2025-06-24T13:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-extends-16-year-research-partnership-with-tsinghua-university-for-three-more-years 2025-06-24T13:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-secures-2-billion-funding-deal-with-royalty-pharma-for-ras-cancer-drug-development 2025-06-24T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-secures-2-billion-funding-deal-with-royalty-pharma-for-ras-cancer-drug-development 2025-06-24T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/brightgene-s-dual-glp-1r-gipr-agonist-bgm0504-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trial 2025-06-24T12:10:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brightgene-s-dual-glp-1r-gipr-agonist-bgm0504-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trial 2025-06-24T12:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/sonrai-analytics-partners-with-plectonic-biotech-to-advance-ai-driven-logic-gated-antibody-cancer-immunotherapies 2025-06-24T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonrai-analytics-partners-with-plectonic-biotech-to-advance-ai-driven-logic-gated-antibody-cancer-immunotherapies 2025-06-24T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-tevimbra-first-immuno-oncology-drug-in-india-for-lung-and-esophageal-cancer-treatment 2025-06-24T12:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-launches-tevimbra-first-immuno-oncology-drug-in-india-for-lung-and-esophageal-cancer-treatment 2025-06-24T12:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/zambon-secures-chinese-approval-for-intravenous-fluimucil-following-successful-phase-3-trial 2025-06-24T12:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zambon-secures-chinese-approval-for-intravenous-fluimucil-following-successful-phase-3-trial 2025-06-24T12:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/australian-clinical-trials-test-antiviral-drugs-targeting-epstein-barr-virus-for-multiple-sclerosis-treatment 2025-06-24T12:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-clinical-trials-test-antiviral-drugs-targeting-epstein-barr-virus-for-multiple-sclerosis-treatment 2025-06-24T12:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-lu-ag13909-receives-orphan-drug-designation-for-congenital-adrenal-hyperplasia-treatment 2025-06-24T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-s-lu-ag13909-receives-orphan-drug-designation-for-congenital-adrenal-hyperplasia-treatment 2025-06-24T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/her2-positive-gastric-cancer-pipeline-shows-robust-activity-with-20-companies-developing-novel-therapies 2025-06-24T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/her2-positive-gastric-cancer-pipeline-shows-robust-activity-with-20-companies-developing-novel-therapies 2025-06-24T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/axcelead-ddp-and-superluminal-expand-partnership-to-target-challenging-biological-mechanisms 2025-06-24T05:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axcelead-ddp-and-superluminal-expand-partnership-to-target-challenging-biological-mechanisms 2025-06-24T05:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/ema-backs-ozempic-label-expansion-for-peripheral-artery-disease-based-on-stride-trial-data 2025-06-24T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-backs-ozempic-label-expansion-for-peripheral-artery-disease-based-on-stride-trial-data 2025-06-24T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/deepecho-receives-fda-510-k-clearance-for-ai-powered-fetal-ultrasound-analysis-platform 2025-06-24T04:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepecho-receives-fda-510-k-clearance-for-ai-powered-fetal-ultrasound-analysis-platform 2025-06-24T04:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/tissium-receives-fda-de-novo-authorization-for-first-atraumatic-sutureless-peripheral-nerve-repair-system 2025-06-24T04:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissium-receives-fda-de-novo-authorization-for-first-atraumatic-sutureless-peripheral-nerve-repair-system 2025-06-24T04:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/psychedelic-therapy-expands-beyond-cancer-care-as-multi-center-studies-launch 2025-06-24T03:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psychedelic-therapy-expands-beyond-cancer-care-as-multi-center-studies-launch 2025-06-24T03:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-receives-south-korean-approval-for-alzheimer-s-biomarker-detection-platform 2025-06-24T03:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanterix-receives-south-korean-approval-for-alzheimer-s-biomarker-detection-platform 2025-06-24T03:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/implantica-completes-fda-pma-submission-for-refluxstop-device-prepares-us-manufacturing-for-gerd-treatment 2025-06-24T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implantica-completes-fda-pma-submission-for-refluxstop-device-prepares-us-manufacturing-for-gerd-treatment 2025-06-24T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-healthcare-innovations-unveils-quattrii-inhaler-technology-to-deliver-large-dose-biologics-and-mrna-therapies 2025-06-24T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-healthcare-innovations-unveils-quattrii-inhaler-technology-to-deliver-large-dose-biologics-and-mrna-therapies 2025-06-24T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-to-report-phase-2b-atopic-dermatitis-trial-results-for-novel-regulatory-t-cell-therapy 2025-06-24T01:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nektar-therapeutics-to-report-phase-2b-atopic-dermatitis-trial-results-for-novel-regulatory-t-cell-therapy 2025-06-24T01:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-to-present-pivotal-data-for-ros1-selective-inhibitor-zidesamtinib-in-advanced-lung-cancer 2025-06-24T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvalent-to-present-pivotal-data-for-ros1-selective-inhibitor-zidesamtinib-in-advanced-lung-cancer 2025-06-24T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-advances-ai-driven-obesity-pipeline-with-myostatin-and-activin-e-antibody-therapies 2025-06-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibio-advances-ai-driven-obesity-pipeline-with-myostatin-and-activin-e-antibody-therapies 2025-06-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-and-doj-complete-final-listening-session-on-drug-price-competition-reforms 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ftc-and-doj-complete-final-listening-session-on-drug-price-competition-reforms 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pathai-receives-fda-clearance-for-aisight-dx-digital-pathology-platform-for-primary-diagnosis 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathai-receives-fda-clearance-for-aisight-dx-digital-pathology-platform-for-primary-diagnosis 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-invests-25-million-in-adagene-s-safebody-platform-for-next-generation-cancer-immunotherapy 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-invests-25-million-in-adagene-s-safebody-platform-for-next-generation-cancer-immunotherapy 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tam-global-appoints-leading-cancer-immunologist-dr-francesco-marincola-as-chief-scientific-officer 2025-06-23T23:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tam-global-appoints-leading-cancer-immunologist-dr-francesco-marincola-as-chief-scientific-officer 2025-06-23T23:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-acting-drug-chief-jacqueline-corrigan-curay-to-retire-amid-leadership-exodus 2025-06-23T22:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-acting-drug-chief-jacqueline-corrigan-curay-to-retire-amid-leadership-exodus 2025-06-23T22:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/australian-government-invests-12-million-in-cardiovascular-and-diabetes-medical-technology-innovation 2025-06-23T22:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-government-invests-12-million-in-cardiovascular-and-diabetes-medical-technology-innovation 2025-06-23T22:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/sichuan-biokin-s-first-in-class-egfr-her3-adc-advances-to-phase-3-trials-across-multiple-cancer-types 2025-06-23T21:43:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sichuan-biokin-s-first-in-class-egfr-her3-adc-advances-to-phase-3-trials-across-multiple-cancer-types 2025-06-23T21:43:33+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-acquires-somalogic-for-425-million-to-accelerate-proteomics-and-multiomics-strategy 2025-06-23T21:13:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-acquires-somalogic-for-425-million-to-accelerate-proteomics-and-multiomics-strategy 2025-06-23T21:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/dr-ashleys-limited-acquires-impact-biomedical-in-strategic-reverse-merger-to-accelerate-global-drug-development 2025-06-23T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-ashleys-limited-acquires-impact-biomedical-in-strategic-reverse-merger-to-accelerate-global-drug-development 2025-06-23T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/lifeplus-achieves-clinical-validation-for-revolutionary-non-invasive-glucose-and-blood-pressure-monitoring-device 2025-06-23T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifeplus-achieves-clinical-validation-for-revolutionary-non-invasive-glucose-and-blood-pressure-monitoring-device 2025-06-23T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-base-editing-shows-promise-for-treating-fatal-pediatric-vascular-disease-msmds 2025-06-23T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-base-editing-shows-promise-for-treating-fatal-pediatric-vascular-disease-msmds 2025-06-23T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-names-charles-schoch-as-permanent-cfo-following-successful-86m-capital-raise 2025-06-23T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-names-charles-schoch-as-permanent-cfo-following-successful-86m-capital-raise 2025-06-23T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/biostem-technologies-completes-enrollment-in-diabetic-foot-ulcer-trial-testing-placental-derived-allograft 2025-06-23T20:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostem-technologies-completes-enrollment-in-diabetic-foot-ulcer-trial-testing-placental-derived-allograft 2025-06-23T20:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/evofem-s-phexxi-hormone-free-contraceptive-seeks-regulatory-approval-in-uae-through-strategic-partnership 2025-06-23T20:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evofem-s-phexxi-hormone-free-contraceptive-seeks-regulatory-approval-in-uae-through-strategic-partnership 2025-06-23T20:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biomedica-achieves-full-ownership-of-us-subsidiary-to-strengthen-global-gene-therapy-manufacturing-network 2025-06-23T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-biomedica-achieves-full-ownership-of-us-subsidiary-to-strengthen-global-gene-therapy-manufacturing-network 2025-06-23T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-guidelines-lag-behind-clinical-practice-as-oncologists-increasingly-adopt-ctdna-testing 2025-06-23T18:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-guidelines-lag-behind-clinical-practice-as-oncologists-increasingly-adopt-ctdna-testing 2025-06-23T18:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/laekna-s-lae102-shows-promising-safety-profile-in-first-in-human-obesity-trial-at-ada-2025 2025-06-23T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laekna-s-lae102-shows-promising-safety-profile-in-first-in-human-obesity-trial-at-ada-2025 2025-06-23T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-bioscience-reaches-50-patent-milestone-with-new-epilepsy-and-nicotine-delivery-patents 2025-06-23T16:59:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-bioscience-reaches-50-patent-milestone-with-new-epilepsy-and-nicotine-delivery-patents 2025-06-23T16:59:21+00:00 hourly 0.9 https://trial.medpath.com/news/carisma-therapeutics-and-orthocellix-announce-25m-merger-to-advance-phase-3-knee-cartilage-therapy 2025-06-23T16:55:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carisma-therapeutics-and-orthocellix-announce-25m-merger-to-advance-phase-3-knee-cartilage-therapy 2025-06-23T16:55:10+00:00 hourly 0.9 https://trial.medpath.com/news/cure-rare-disease-advances-lgmdr9-gene-therapy-following-positive-fda-pre-ind-meeting 2025-06-23T16:55:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cure-rare-disease-advances-lgmdr9-gene-therapy-following-positive-fda-pre-ind-meeting 2025-06-23T16:55:05+00:00 hourly 0.9 https://trial.medpath.com/news/fujirebio-acquires-plasma-services-group-to-strengthen-rare-disease-biomarker-supply-chain 2025-06-23T16:55:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujirebio-acquires-plasma-services-group-to-strengthen-rare-disease-biomarker-supply-chain 2025-06-23T16:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-to-present-phase-2-data-for-arct-810-mrna-therapy-in-rare-genetic-disorder 2025-06-23T16:53:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-to-present-phase-2-data-for-arct-810-mrna-therapy-in-rare-genetic-disorder 2025-06-23T16:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-licenses-dual-jak-syk-inhibitor-gusacitinib-from-formation-bio-in-eur545-million-deal 2025-06-23T16:50:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-licenses-dual-jak-syk-inhibitor-gusacitinib-from-formation-bio-in-eur545-million-deal 2025-06-23T16:50:27+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-reports-positive-phase-2-results-for-ifetroban-in-duchenne-muscular-dystrophy-heart-disease 2025-06-23T16:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumberland-pharmaceuticals-reports-positive-phase-2-results-for-ifetroban-in-duchenne-muscular-dystrophy-heart-disease 2025-06-23T16:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/oryzon-submits-phase-iii-protocol-for-vafidemstat-in-borderline-personality-disorder-targeting-first-fda-approved-treatment 2025-06-23T16:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oryzon-submits-phase-iii-protocol-for-vafidemstat-in-borderline-personality-disorder-targeting-first-fda-approved-treatment 2025-06-23T16:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/denovo-biopharma-out-licenses-biomarker-guided-depression-drug-db104-to-taiwan-partner 2025-06-23T16:11:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denovo-biopharma-out-licenses-biomarker-guided-depression-drug-db104-to-taiwan-partner 2025-06-23T16:11:37+00:00 hourly 0.9 https://trial.medpath.com/news/viromed-s-cold-plasma-technology-demonstrates-potential-to-prevent-6000-deaths-annually-from-ventilator-associated-pneumonia 2025-06-23T16:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viromed-s-cold-plasma-technology-demonstrates-potential-to-prevent-6000-deaths-annually-from-ventilator-associated-pneumonia 2025-06-23T16:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-bone-growth-accelerator-for-spinal-fusion-surgery 2025-06-23T16:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-bone-growth-accelerator-for-spinal-fusion-surgery 2025-06-23T16:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/vsee-health-selected-for-nih-funded-phase-3-stroke-telerehabilitation-trial-across-29-hospitals 2025-06-23T16:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vsee-health-selected-for-nih-funded-phase-3-stroke-telerehabilitation-trial-across-29-hospitals 2025-06-23T16:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/angiodynamics-initiates-recover-av-trial-for-pulmonary-embolism-treatment-device 2025-06-23T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angiodynamics-initiates-recover-av-trial-for-pulmonary-embolism-treatment-device 2025-06-23T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/altrubio-s-altb-268-shows-promise-in-preclinical-models-of-inflammatory-diseases-supporting-phase-2-uc-trial 2025-06-23T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altrubio-s-altb-268-shows-promise-in-preclinical-models-of-inflammatory-diseases-supporting-phase-2-uc-trial 2025-06-23T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/new-analysis-shows-radicava-ors-extends-survival-and-slows-functional-decline-in-als-patients 2025-06-23T13:39:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-analysis-shows-radicava-ors-extends-survival-and-slows-functional-decline-in-als-patients 2025-06-23T13:39:58+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-treatment-strategies-and-adverse-event-management-transform-mcrpc-care 2025-06-23T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-treatment-strategies-and-adverse-event-management-transform-mcrpc-care 2025-06-23T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/monument-therapeutics-reports-positive-phase-i-results-for-novel-schizophrenia-cognitive-treatment-mt1988 2025-06-23T13:17:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monument-therapeutics-reports-positive-phase-i-results-for-novel-schizophrenia-cognitive-treatment-mt1988 2025-06-23T13:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/penn-researchers-transform-deadly-aspergillus-fungus-into-potent-anti-leukemia-drug 2025-06-23T13:14:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-researchers-transform-deadly-aspergillus-fungus-into-potent-anti-leukemia-drug 2025-06-23T13:14:26+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-strengthens-leadership-with-endocrinology-expert-to-advance-hypoparathyroidism-treatment 2025-06-23T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbx-biosciences-strengthens-leadership-with-endocrinology-expert-to-advance-hypoparathyroidism-treatment 2025-06-23T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-icovamenib-shows-promise-in-combination-with-glp-1-therapies-for-type-2-diabetes 2025-06-23T13:12:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomea-fusion-s-icovamenib-shows-promise-in-combination-with-glp-1-therapies-for-type-2-diabetes 2025-06-23T13:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/itm-and-debiopharm-initiate-new-study-arm-for-caix-targeted-theranostic-in-clear-cell-renal-cell-carcinoma 2025-06-23T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-and-debiopharm-initiate-new-study-arm-for-caix-targeted-theranostic-in-clear-cell-renal-cell-carcinoma 2025-06-23T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-imp761-shows-80-t-cell-suppression-in-phase-i-autoimmune-disease-trial 2025-06-23T13:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-s-imp761-shows-80-t-cell-suppression-in-phase-i-autoimmune-disease-trial 2025-06-23T13:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/novadip-receives-fda-rmat-designation-for-nvd003-regenerative-therapy-in-rare-pediatric-bone-disease 2025-06-23T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novadip-receives-fda-rmat-designation-for-nvd003-regenerative-therapy-in-rare-pediatric-bone-disease 2025-06-23T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/spanish-researchers-develop-dna-test-to-predict-chemotherapy-resistance-clinical-trials-set-for-2026 2025-06-23T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spanish-researchers-develop-dna-test-to-predict-chemotherapy-resistance-clinical-trials-set-for-2026 2025-06-23T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-alvotech-s-biosimilar-to-eylea-for-eye-disorders 2025-06-23T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-approval-of-alvotech-s-biosimilar-to-eylea-for-eye-disorders 2025-06-23T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/clinuvel-ceo-returns-to-drive-us-expansion-with-vitiligo-treatment-approval-strategy 2025-06-23T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinuvel-ceo-returns-to-drive-us-expansion-with-vitiligo-treatment-approval-strategy 2025-06-23T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionxt-launches-feasibility-study-for-oral-dissolvable-film-semaglutide-delivery 2025-06-23T13:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionxt-launches-feasibility-study-for-oral-dissolvable-film-semaglutide-delivery 2025-06-23T13:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-completes-enrollment-of-phase-3-trial-for-once-daily-oral-pah-treatment-ralinepag 2025-06-23T13:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-completes-enrollment-of-phase-3-trial-for-once-daily-oral-pah-treatment-ralinepag 2025-06-23T13:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-and-ono-pharmaceutical-form-strategic-alliance-for-povetacicept-development-in-japan-and-south-korea 2025-06-23T13:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-and-ono-pharmaceutical-form-strategic-alliance-for-povetacicept-development-in-japan-and-south-korea 2025-06-23T13:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-s-quviviq-receives-approval-in-china-for-insomnia-treatment-through-simcere-partnership 2025-06-23T10:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idorsia-s-quviviq-receives-approval-in-china-for-insomnia-treatment-through-simcere-partnership 2025-06-23T10:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/progenis-pharmaceuticals-secures-mtpconnect-funding-for-novel-rna-based-type-2-diabetes-treatment 2025-06-23T08:55:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/progenis-pharmaceuticals-secures-mtpconnect-funding-for-novel-rna-based-type-2-diabetes-treatment 2025-06-23T08:55:42+00:00 hourly 0.9 https://trial.medpath.com/news/carmil2-gain-of-function-mutation-shows-promise-for-next-generation-cancer-immunotherapies 2025-06-23T08:55:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carmil2-gain-of-function-mutation-shows-promise-for-next-generation-cancer-immunotherapies 2025-06-23T08:55:40+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-nxt007-achieves-zero-bleeds-in-phase-i-ii-hemophilia-a-trial-advances-to-phase-iii 2025-06-23T08:54:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-nxt007-achieves-zero-bleeds-in-phase-i-ii-hemophilia-a-trial-advances-to-phase-iii 2025-06-23T08:54:46+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-appoints-former-horizon-cfo-aaron-cox-to-lead-strategic-transformation 2025-06-23T08:54:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-appoints-former-horizon-cfo-aaron-cox-to-lead-strategic-transformation 2025-06-23T08:54:24+00:00 hourly 0.9 https://trial.medpath.com/news/utopia-therapeutics-secures-1-5m-for-novel-obesity-vaccine-ut009 2025-06-23T08:54:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/utopia-therapeutics-secures-1-5m-for-novel-obesity-vaccine-ut009 2025-06-23T08:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/primary-biliary-cholangitis-pipeline-shows-strong-progress-with-multiple-late-stage-therapies-and-recent-fda-approvals 2025-06-23T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/primary-biliary-cholangitis-pipeline-shows-strong-progress-with-multiple-late-stage-therapies-and-recent-fda-approvals 2025-06-23T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-pharmaceutical-secures-global-rights-to-hbm7020-bcmaxcd3-bispecific-t-cell-engager-for-autoimmune-diseases 2025-06-23T05:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-pharmaceutical-secures-global-rights-to-hbm7020-bcmaxcd3-bispecific-t-cell-engager-for-autoimmune-diseases 2025-06-23T05:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/water-consumption-doubles-diabetes-remission-rates-compared-to-diet-beverages-in-clinical-study 2025-06-23T05:00:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/water-consumption-doubles-diabetes-remission-rates-compared-to-diet-beverages-in-clinical-study 2025-06-23T05:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/xtalpi-secures-100-million-partnership-with-harvard-s-gregory-verdine-to-advance-ai-driven-drug-discovery 2025-06-23T04:11:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtalpi-secures-100-million-partnership-with-harvard-s-gregory-verdine-to-advance-ai-driven-drug-discovery 2025-06-23T04:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/major-food-companies-eliminate-artificial-dyes-following-fda-push-and-health-concerns 2025-06-23T04:05:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-food-companies-eliminate-artificial-dyes-following-fda-push-and-health-concerns 2025-06-23T04:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-international-launches-next-generation-promarkerd-test-for-early-diabetic-kidney-disease-detection-in-us-market 2025-06-23T00:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomics-international-launches-next-generation-promarkerd-test-for-early-diabetic-kidney-disease-detection-in-us-market 2025-06-23T00:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-industry-faces-wave-of-strategic-layoffs-as-companies-prioritize-efficiency-and-pipeline-focus 2025-06-23T00:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-industry-faces-wave-of-strategic-layoffs-as-companies-prioritize-efficiency-and-pipeline-focus 2025-06-23T00:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/sonrotoclax-plus-zanubrutinib-shows-promise-in-relapsed-refractory-mantle-cell-lymphoma-with-78-response-rate 2025-06-22T21:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonrotoclax-plus-zanubrutinib-shows-promise-in-relapsed-refractory-mantle-cell-lymphoma-with-78-response-rate 2025-06-22T21:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-mim8-shows-safe-direct-switch-from-emicizumab-in-phase-3b-hemophilia-a-trial 2025-06-22T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-mim8-shows-safe-direct-switch-from-emicizumab-in-phase-3b-hemophilia-a-trial 2025-06-22T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-once-weekly-insulin-efsitora-alfa-achieves-non-inferiority-in-phase-3-trials-reducing-injection-burden-by-300-doses-annually 2025-06-22T20:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-once-weekly-insulin-efsitora-alfa-achieves-non-inferiority-in-phase-3-trials-reducing-injection-burden-by-300-doses-annually 2025-06-22T20:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/russia-initiates-phase-i-clinical-trial-for-enteromix-cancer-vaccine-based-on-four-non-pathogenic-viruses 2025-06-22T17:05:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/russia-initiates-phase-i-clinical-trial-for-enteromix-cancer-vaccine-based-on-four-non-pathogenic-viruses 2025-06-22T17:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-oral-diabetes-drug-orforglipron-shows-promise-in-phase-3-trial-offering-alternative-to-injectable-glp-1-therapies 2025-06-22T09:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-oral-diabetes-drug-orforglipron-shows-promise-in-phase-3-trial-offering-alternative-to-injectable-glp-1-therapies 2025-06-22T09:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-startup-s-urine-based-cancer-test-detects-stage-0-lung-cancer-in-hokkaido-pilot-study 2025-06-22T04:48:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-startup-s-urine-based-cancer-test-detects-stage-0-lung-cancer-in-hokkaido-pilot-study 2025-06-22T04:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/magellan-stem-cells-receives-tga-manufacturing-license-advancing-australia-s-cell-therapy-independence 2025-06-22T04:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magellan-stem-cells-receives-tga-manufacturing-license-advancing-australia-s-cell-therapy-independence 2025-06-22T04:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lenacapavir-for-hiv-prevention-with-99-9-efficacy-but-high-cost-raises-accessibility-concerns-in-india 2025-06-22T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lenacapavir-for-hiv-prevention-with-99-9-efficacy-but-high-cost-raises-accessibility-concerns-in-india 2025-06-22T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-advance-nanoscale-drug-delivery-systems-with-targeted-cell-recognition-and-biological-signal-response 2025-06-22T01:03:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-advance-nanoscale-drug-delivery-systems-with-targeted-cell-recognition-and-biological-signal-response 2025-06-22T01:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/abvance-therapeutics-presents-first-human-data-on-fixed-ratio-insulin-glucagon-combination-for-type-1-diabetes 2025-06-22T01:02:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abvance-therapeutics-presents-first-human-data-on-fixed-ratio-insulin-glucagon-combination-for-type-1-diabetes 2025-06-22T01:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-kesimpta-shows-sustained-efficacy-in-multiple-sclerosis-patients-over-seven-years 2025-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-kesimpta-shows-sustained-efficacy-in-multiple-sclerosis-patients-over-seven-years 2025-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-radioligand-therapy-177lu-lu-neob-enters-clinical-testing-for-advanced-breast-cancer 2025-06-21T23:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-radioligand-therapy-177lu-lu-neob-enters-clinical-testing-for-advanced-breast-cancer 2025-06-21T23:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/sai-life-sciences-completes-major-capacity-expansion-at-bidar-manufacturing-facility 2025-06-21T21:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sai-life-sciences-completes-major-capacity-expansion-at-bidar-manufacturing-facility 2025-06-21T21:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-delivery-technology-aims-to-prevent-opioid-overdoses-through-controlled-release 2025-06-21T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-drug-delivery-technology-aims-to-prevent-opioid-overdoses-through-controlled-release 2025-06-21T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-eptinezumab-shows-strong-efficacy-in-asian-chronic-migraine-patients-in-phase-iii-sunrise-trial 2025-06-21T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-s-eptinezumab-shows-strong-efficacy-in-asian-chronic-migraine-patients-in-phase-iii-sunrise-trial 2025-06-21T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/unc-lineberger-cancer-center-leads-28-million-arpa-h-trial-to-revolutionize-metastatic-breast-cancer-treatment 2025-06-21T14:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unc-lineberger-cancer-center-leads-28-million-arpa-h-trial-to-revolutionize-metastatic-breast-cancer-treatment 2025-06-21T14:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/gan-lee-s-bofanglutide-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trials 2025-06-21T13:00:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gan-lee-s-bofanglutide-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trials 2025-06-21T13:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-minimed-780g-system-shows-promise-for-type-2-diabetes-and-young-children-with-type-1-diabetes 2025-06-21T06:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-minimed-780g-system-shows-promise-for-type-2-diabetes-and-young-children-with-type-1-diabetes 2025-06-21T06:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/verdiva-bio-advances-once-weekly-oral-glp-1-and-amylin-therapies-for-obesity-treatment 2025-06-21T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verdiva-bio-advances-once-weekly-oral-glp-1-and-amylin-therapies-for-obesity-treatment 2025-06-21T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-pharmacists-demonstrate-significant-cost-savings-and-expanded-clinical-roles-through-remote-services-and-ai-integration 2025-06-21T03:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-pharmacists-demonstrate-significant-cost-savings-and-expanded-clinical-roles-through-remote-services-and-ai-integration 2025-06-21T03:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/ema-initiates-review-of-sodium-oxybate-for-alcohol-dependence-following-efficacy-and-safety-concerns 2025-06-21T01:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-initiates-review-of-sodium-oxybate-for-alcohol-dependence-following-efficacy-and-safety-concerns 2025-06-21T01:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-promising-survival-rates-for-stem-cell-transplants-from-mismatched-unrelated-donors 2025-06-21T00:14:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-shows-promising-survival-rates-for-stem-cell-transplants-from-mismatched-unrelated-donors 2025-06-21T00:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/pharmala-files-c-50-million-shelf-prospectus-to-advance-mdma-drug-development 2025-06-21T00:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmala-files-c-50-million-shelf-prospectus-to-advance-mdma-drug-development 2025-06-21T00:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-diabetes-drug-liraglutide-reduces-migraine-days-by-half-in-pilot-study 2025-06-21T00:12:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-diabetes-drug-liraglutide-reduces-migraine-days-by-half-in-pilot-study 2025-06-21T00:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/cansinobio-launches-ipneucia-r-13-valent-pneumococcal-vaccine-optimized-for-chinese-children 2025-06-20T22:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cansinobio-launches-ipneucia-r-13-valent-pneumococcal-vaccine-optimized-for-chinese-children 2025-06-20T22:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-expands-patent-protection-for-aflibercept-with-new-formulation-patent-against-amgen 2025-06-20T21:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-expands-patent-protection-for-aflibercept-with-new-formulation-patent-against-amgen 2025-06-20T21:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/gh-research-submits-ind-hold-response-to-fda-for-depression-treatment-gh001-ahead-of-schedule 2025-06-20T21:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gh-research-submits-ind-hold-response-to-fda-for-depression-treatment-gh001-ahead-of-schedule 2025-06-20T21:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/cereno-scientific-secures-100-msek-financing-to-advance-hdac-inhibitor-pipeline-for-rare-cardiovascular-and-pulmonary-diseases 2025-06-20T19:15:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cereno-scientific-secures-100-msek-financing-to-advance-hdac-inhibitor-pipeline-for-rare-cardiovascular-and-pulmonary-diseases 2025-06-20T19:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-secures-multiple-fda-approvals-for-generic-drug-portfolio-expansion 2025-06-20T18:14:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-secures-multiple-fda-approvals-for-generic-drug-portfolio-expansion 2025-06-20T18:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/candid-therapeutics-doses-first-patients-with-novel-t-cell-engagers-for-autoimmune-diseases 2025-06-20T18:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candid-therapeutics-doses-first-patients-with-novel-t-cell-engagers-for-autoimmune-diseases 2025-06-20T18:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/dutch-court-upholds-xtandi-patent-protection-blocking-generic-enzalutamide-launch-until-2028 2025-06-20T16:56:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dutch-court-upholds-xtandi-patent-protection-blocking-generic-enzalutamide-launch-until-2028 2025-06-20T16:56:18+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-bct-unveils-automated-car-t-manufacturing-platform-delivering-12-billion-cells-in-7-8-days 2025-06-20T16:56:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terumo-bct-unveils-automated-car-t-manufacturing-platform-delivering-12-billion-cells-in-7-8-days 2025-06-20T16:56:09+00:00 hourly 0.9 https://trial.medpath.com/news/lomond-therapeutics-receives-fda-clearance-for-phase-1-trial-of-lonitoclax-in-relapsed-refractory-aml 2025-06-20T16:55:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lomond-therapeutics-receives-fda-clearance-for-phase-1-trial-of-lonitoclax-in-relapsed-refractory-aml 2025-06-20T16:55:40+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-receives-positive-chmp-opinion-for-ustekinumab-biosimilar-usymro 2025-06-20T16:53:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-thera-solutions-receives-positive-chmp-opinion-for-ustekinumab-biosimilar-usymro 2025-06-20T16:53:39+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-biotech-raises-5-9-million-to-advance-annamycin-through-phase-3-aml-trial 2025-06-20T16:52:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moleculin-biotech-raises-5-9-million-to-advance-annamycin-through-phase-3-aml-trial 2025-06-20T16:52:23+00:00 hourly 0.9 https://trial.medpath.com/news/onco360-partners-with-deciphera-to-distribute-qinlock-for-advanced-gist-patients 2025-06-20T16:14:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco360-partners-with-deciphera-to-distribute-qinlock-for-advanced-gist-patients 2025-06-20T16:14:58+00:00 hourly 0.9 https://trial.medpath.com/news/perceptive-discovery-and-pfizer-launch-fibre-consortium-to-advance-fibrosis-drug-development-through-advanced-imaging 2025-06-20T16:14:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perceptive-discovery-and-pfizer-launch-fibre-consortium-to-advance-fibrosis-drug-development-through-advanced-imaging 2025-06-20T16:14:43+00:00 hourly 0.9 https://trial.medpath.com/news/shine-technologies-lutetium-177-isotope-ilumira-reaches-global-milestone-with-19-country-distribution-network 2025-06-20T16:14:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shine-technologies-lutetium-177-isotope-ilumira-reaches-global-milestone-with-19-country-distribution-network 2025-06-20T16:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/european-medicines-agency-recommends-approval-of-partner-therapeutics-imreplys-for-acute-radiation-syndrome-treatment 2025-06-20T16:14:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-medicines-agency-recommends-approval-of-partner-therapeutics-imreplys-for-acute-radiation-syndrome-treatment 2025-06-20T16:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-biotherapeutics-pivots-to-bitcoin-treasury-strategy-following-clinical-trial-failures 2025-06-20T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridge-biotherapeutics-pivots-to-bitcoin-treasury-strategy-following-clinical-trial-failures 2025-06-20T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuno-cure-partners-with-pharmajet-to-advance-hiv-therapeutic-dna-vaccine-using-needle-free-delivery-technology 2025-06-20T15:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuno-cure-partners-with-pharmajet-to-advance-hiv-therapeutic-dna-vaccine-using-needle-free-delivery-technology 2025-06-20T15:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/valirx-secures-ps16-million-licensing-deal-for-repurposed-risperidone-cancer-therapy-val401 2025-06-20T14:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valirx-secures-ps16-million-licensing-deal-for-repurposed-risperidone-cancer-therapy-val401 2025-06-20T14:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/european-phase-ii-trial-tests-simple-home-intervention-to-prevent-heart-failure-in-cancer-survivors 2025-06-20T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-phase-ii-trial-tests-simple-home-intervention-to-prevent-heart-failure-in-cancer-survivors 2025-06-20T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-first-risk-prediction-model-for-early-stage-hodgkin-s-lymphoma 2025-06-20T10:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-first-risk-prediction-model-for-early-stage-hodgkin-s-lymphoma 2025-06-20T10:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/altum-sequencing-s-liquid-biopsy-technology-detects-breast-cancer-relapse-up-to-68-months-before-clinical-symptoms 2025-06-20T08:48:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altum-sequencing-s-liquid-biopsy-technology-detects-breast-cancer-relapse-up-to-68-months-before-clinical-symptoms 2025-06-20T08:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/xjtlu-scientists-develop-ultra-stable-nanoparticles-with-40-drug-loading-capacity-for-enhanced-cancer-treatment 2025-06-20T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xjtlu-scientists-develop-ultra-stable-nanoparticles-with-40-drug-loading-capacity-for-enhanced-cancer-treatment 2025-06-20T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/bmj-investigation-uncovers-data-integrity-issues-in-astrazeneca-s-ticagrelor-heart-drug-trials 2025-06-20T05:02:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bmj-investigation-uncovers-data-integrity-issues-in-astrazeneca-s-ticagrelor-heart-drug-trials 2025-06-20T05:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/hkbu-researchers-engineer-exosomes-to-deliver-alzheimer-s-drug-across-blood-brain-barrier 2025-06-20T04:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hkbu-researchers-engineer-exosomes-to-deliver-alzheimer-s-drug-across-blood-brain-barrier 2025-06-20T04:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/cube-click-secures-fda-approval-for-smile-dx-ai-powered-dental-diagnostic-platform 2025-06-20T03:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cube-click-secures-fda-approval-for-smile-dx-ai-powered-dental-diagnostic-platform 2025-06-20T03:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/chemotherapy-free-regimens-and-car-t-therapies-transform-b-cell-malignancy-treatment-paradigms 2025-06-20T03:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemotherapy-free-regimens-and-car-t-therapies-transform-b-cell-malignancy-treatment-paradigms 2025-06-20T03:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/expert-panel-identifies-key-patient-factors-for-optimizing-immunotherapy-selection-in-pd-l1-negative-nsclc 2025-06-20T03:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-panel-identifies-key-patient-factors-for-optimizing-immunotherapy-selection-in-pd-l1-negative-nsclc 2025-06-20T03:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-shows-consistent-efficacy-in-cervical-cancer-regardless-of-pd-l1-status-beatcc-trial-analysis-reveals 2025-06-20T02:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-shows-consistent-efficacy-in-cervical-cancer-regardless-of-pd-l1-status-beatcc-trial-analysis-reveals 2025-06-20T02:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-secures-2-billion-option-deal-for-gilgamesh-s-next-generation-psychedelic-therapies 2025-06-20T01:40:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-secures-2-billion-option-deal-for-gilgamesh-s-next-generation-psychedelic-therapies 2025-06-20T01:40:54+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-wisconsin-researchers-develop-personalized-cancer-vaccines-using-pyroptotic-vesicles-to-prevent-tumor-recurrence 2025-06-20T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-wisconsin-researchers-develop-personalized-cancer-vaccines-using-pyroptotic-vesicles-to-prevent-tumor-recurrence 2025-06-20T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-treatment-for-atopic-dermatitis-linked-to-increased-psoriasis-risk-in-large-scale-study 2025-06-20T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-treatment-for-atopic-dermatitis-linked-to-increased-psoriasis-risk-in-large-scale-study 2025-06-20T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-fibrinogen-concentrate-bt524-demonstrates-non-inferiority-in-phase-iii-trial-for-surgical-bleeding 2025-06-20T00:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grifols-fibrinogen-concentrate-bt524-demonstrates-non-inferiority-in-phase-iii-trial-for-surgical-bleeding 2025-06-20T00:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/dgenthera-and-nusano-partner-to-scale-astatine-211-production-for-next-generation-cancer-therapy 2025-06-20T00:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dgenthera-and-nusano-partner-to-scale-astatine-211-production-for-next-generation-cancer-therapy 2025-06-20T00:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/historical-challenges-in-nf1-associated-plexiform-neurofibroma-treatment-drive-development-of-targeted-therapies 2025-06-20T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/historical-challenges-in-nf1-associated-plexiform-neurofibroma-treatment-drive-development-of-targeted-therapies 2025-06-20T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/dendritic-cell-therapy-shows-significant-survival-benefit-for-recurrent-glioblastoma-patients 2025-06-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dendritic-cell-therapy-shows-significant-survival-benefit-for-recurrent-glioblastoma-patients 2025-06-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/prothena-cuts-63-of-workforce-as-company-restructures-operations-amid-pipeline-milestones 2025-06-19T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prothena-cuts-63-of-workforce-as-company-restructures-operations-amid-pipeline-milestones 2025-06-19T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/cd5-targeted-therapies-show-promise-across-cancer-autoimmunity-and-transplantation-with-first-commercial-launch-expected-by-2030 2025-06-19T21:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd5-targeted-therapies-show-promise-across-cancer-autoimmunity-and-transplantation-with-first-commercial-launch-expected-by-2030 2025-06-19T21:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-iii-essential-thrombocythemia-trial 2025-06-19T21:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-iii-essential-thrombocythemia-trial 2025-06-19T21:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/zilia-ocular-receives-world-first-health-canada-approval-for-non-invasive-retinal-oxygen-measurement 2025-06-19T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zilia-ocular-receives-world-first-health-canada-approval-for-non-invasive-retinal-oxygen-measurement 2025-06-19T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/cns-oligonucleotide-licensing-deals-surge-339-to-2-81-billion-in-2024 2025-06-19T20:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cns-oligonucleotide-licensing-deals-surge-339-to-2-81-billion-in-2024 2025-06-19T20:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/beta-bionics-partners-with-abbott-to-integrate-ilet-bionic-pancreas-with-future-dual-glucose-ketone-sensor 2025-06-19T18:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beta-bionics-partners-with-abbott-to-integrate-ilet-bionic-pancreas-with-future-dual-glucose-ketone-sensor 2025-06-19T18:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-immunoglobulin-with-hyaluronidase-shows-promise-for-idiopathic-inflammatory-myositis-treatment 2025-06-19T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-immunoglobulin-with-hyaluronidase-shows-promise-for-idiopathic-inflammatory-myositis-treatment 2025-06-19T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/theranica-s-nerivio-ren-wearable-shows-sustained-migraine-efficacy-over-three-years-in-real-world-studies 2025-06-19T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theranica-s-nerivio-ren-wearable-shows-sustained-migraine-efficacy-over-three-years-in-real-world-studies 2025-06-19T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/tocilizumab-biosimilar-ct-p47-demonstrates-long-term-efficacy-and-safety-in-rheumatoid-arthritis-treatment 2025-06-19T17:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tocilizumab-biosimilar-ct-p47-demonstrates-long-term-efficacy-and-safety-in-rheumatoid-arthritis-treatment 2025-06-19T17:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-treatment-for-alkaptonuria-nitisinone-shows-clinical-benefits-in-rare-metabolic-disorder 2025-06-19T17:05:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-treatment-for-alkaptonuria-nitisinone-shows-clinical-benefits-in-rare-metabolic-disorder 2025-06-19T17:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/excellthera-s-zemcelpro-receives-positive-chmp-opinion-for-blood-cancer-patients-without-suitable-donors 2025-06-19T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excellthera-s-zemcelpro-receives-positive-chmp-opinion-for-blood-cancer-patients-without-suitable-donors 2025-06-19T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-analytics-summits-address-critical-quality-control-challenges-amid-regulatory-setbacks 2025-06-19T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-analytics-summits-address-critical-quality-control-challenges-amid-regulatory-setbacks 2025-06-19T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-increased-risk-of-gallbladder-disease-in-large-scale-safety-analysis 2025-06-19T16:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-increased-risk-of-gallbladder-disease-in-large-scale-safety-analysis 2025-06-19T16:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/brenus-pharma-and-insphero-develop-advanced-3d-tumor-models-for-colorectal-cancer-immunotherapy-testing 2025-06-19T15:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brenus-pharma-and-insphero-develop-advanced-3d-tumor-models-for-colorectal-cancer-immunotherapy-testing 2025-06-19T15:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/bionova-scientific-expands-into-advanced-therapies-with-third-flexfactory-platform-installation 2025-06-19T15:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionova-scientific-expands-into-advanced-therapies-with-third-flexfactory-platform-installation 2025-06-19T15:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-bmf-650-demonstrates-significant-weight-loss-in-primate-study-advancing-toward-clinical-trials 2025-06-19T13:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomea-fusion-s-bmf-650-demonstrates-significant-weight-loss-in-primate-study-advancing-toward-clinical-trials 2025-06-19T13:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/pleopharma-s-pp-01-shows-significant-efficacy-in-phase-2b-trial-for-cannabis-withdrawal-syndrome 2025-06-19T13:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pleopharma-s-pp-01-shows-significant-efficacy-in-phase-2b-trial-for-cannabis-withdrawal-syndrome 2025-06-19T13:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-pharmacopeia-recognizes-mass-photometry-as-key-method-for-aav-gene-therapy-quality-standards 2025-06-19T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-pharmacopeia-recognizes-mass-photometry-as-key-method-for-aav-gene-therapy-quality-standards 2025-06-19T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/kras-g12c-nsclc-patients-face-limited-cns-treatment-options-despite-40-brain-metastases-rate 2025-06-19T13:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kras-g12c-nsclc-patients-face-limited-cns-treatment-options-despite-40-brain-metastases-rate 2025-06-19T13:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/memo-therapeutics-to-present-phase-ii-results-for-first-in-class-bk-polyomavirus-treatment-at-world-transplant-congress 2025-06-19T12:15:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memo-therapeutics-to-present-phase-ii-results-for-first-in-class-bk-polyomavirus-treatment-at-world-transplant-congress 2025-06-19T12:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/doe-supplies-accelerator-produced-actinium-225-for-first-ever-u-s-cancer-therapy-clinical-trial 2025-06-19T11:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doe-supplies-accelerator-produced-actinium-225-for-first-ever-u-s-cancer-therapy-clinical-trial 2025-06-19T11:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/synfini-and-o2nix-bio-partner-to-develop-ai-driven-cancer-metastasis-therapies-targeting-ftsj1 2025-06-19T09:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synfini-and-o2nix-bio-partner-to-develop-ai-driven-cancer-metastasis-therapies-targeting-ftsj1 2025-06-19T09:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cancels-advisory-committee-meeting-for-capricor-s-duchenne-therapy-amid-leadership-shake-up 2025-06-19T09:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-cancels-advisory-committee-meeting-for-capricor-s-duchenne-therapy-amid-leadership-shake-up 2025-06-19T09:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/medhub-ai-receives-pmda-approval-for-ai-powered-coronary-assessment-technology-in-japan 2025-06-19T09:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medhub-ai-receives-pmda-approval-for-ai-powered-coronary-assessment-technology-in-japan 2025-06-19T09:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/tgs-and-viridien-launch-laconia-phase-iii-ocean-bottom-node-survey-in-gulf-of-america 2025-06-19T08:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tgs-and-viridien-launch-laconia-phase-iii-ocean-bottom-node-survey-in-gulf-of-america 2025-06-19T08:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/hotspot-therapeutics-to-present-irf5-small-molecule-inhibitor-data-at-focis-2025 2025-06-19T07:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hotspot-therapeutics-to-present-irf5-small-molecule-inhibitor-data-at-focis-2025 2025-06-19T07:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/simcere-zaiming-initiates-us-phase-1-trial-of-trispecific-antibody-sim0500-for-relapsed-refractory-multiple-myeloma 2025-06-19T05:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simcere-zaiming-initiates-us-phase-1-trial-of-trispecific-antibody-sim0500-for-relapsed-refractory-multiple-myeloma 2025-06-19T05:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/saptalis-pharmaceuticals-launches-fluoxetine-oral-solution-for-multiple-mental-health-conditions 2025-06-19T05:03:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saptalis-pharmaceuticals-launches-fluoxetine-oral-solution-for-multiple-mental-health-conditions 2025-06-19T05:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-oncology-pharmacists-emerge-as-critical-players-in-personalized-cancer-care 2025-06-19T03:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-oncology-pharmacists-emerge-as-critical-players-in-personalized-cancer-care 2025-06-19T03:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/insulet-presents-real-world-evidence-of-omnipod-5-benefits-in-type-2-diabetes-at-ada-2025 2025-06-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insulet-presents-real-world-evidence-of-omnipod-5-benefits-in-type-2-diabetes-at-ada-2025 2025-06-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-shuts-down-maryland-cell-therapy-manufacturing-following-car-t-trial-failure 2025-06-19T01:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-shuts-down-maryland-cell-therapy-manufacturing-following-car-t-trial-failure 2025-06-19T01:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-critical-safety-warning-for-scopolamine-patch-following-13-global-hyperthermia-cases 2025-06-19T01:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-critical-safety-warning-for-scopolamine-patch-following-13-global-hyperthermia-cases 2025-06-19T01:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/kindeva-partners-with-rocket-science-health-to-advance-novel-intranasal-cns-drug-delivery-platform 2025-06-19T01:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kindeva-partners-with-rocket-science-health-to-advance-novel-intranasal-cns-drug-delivery-platform 2025-06-19T01:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-halts-clinical-trials-sending-american-cells-to-foreign-labs-for-genetic-engineering 2025-06-19T00:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-halts-clinical-trials-sending-american-cells-to-foreign-labs-for-genetic-engineering 2025-06-19T00:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-reveals-46-cognitive-decline-reduction-in-alzheimer-s-trial-reanalysis 2025-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-reveals-46-cognitive-decline-reduction-in-alzheimer-s-trial-reanalysis 2025-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/genecentric-secures-8m-series-c-to-commercialize-rna-based-liquid-biopsy-platform 2025-06-18T22:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genecentric-secures-8m-series-c-to-commercialize-rna-based-liquid-biopsy-platform 2025-06-18T22:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/avalo-therapeutics-appoints-rita-jain-to-board-as-avtx-009-phase-2-trial-for-hidradenitis-suppurativa-progresses 2025-06-18T21:13:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalo-therapeutics-appoints-rita-jain-to-board-as-avtx-009-phase-2-trial-for-hidradenitis-suppurativa-progresses 2025-06-18T21:13:30+00:00 hourly 0.9 https://trial.medpath.com/news/kaiser-permanente-launches-fda-approved-gene-therapy-program-for-pediatric-sickle-cell-disease 2025-06-18T21:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaiser-permanente-launches-fda-approved-gene-therapy-program-for-pediatric-sickle-cell-disease 2025-06-18T21:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tafasitamab-triple-combination-for-relapsed-refractory-follicular-lymphoma 2025-06-18T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tafasitamab-triple-combination-for-relapsed-refractory-follicular-lymphoma 2025-06-18T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/eccogene-initiates-phase-1b-trial-of-novel-oral-glp-1-receptor-agonist-azd5004-ecc5004-in-china 2025-06-18T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eccogene-initiates-phase-1b-trial-of-novel-oral-glp-1-receptor-agonist-azd5004-ecc5004-in-china 2025-06-18T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/dapagliflozin-combination-therapy-shows-promise-for-adolescents-with-type-1-diabetes-in-clinical-trial 2025-06-18T20:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dapagliflozin-combination-therapy-shows-promise-for-adolescents-with-type-1-diabetes-in-clinical-trial 2025-06-18T20:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-expands-tecnis-odyssey-iol-to-europe-middle-east-and-canada-following-us-success 2025-06-18T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-expands-tecnis-odyssey-iol-to-europe-middle-east-and-canada-following-us-success 2025-06-18T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/camurus-cam2029-shows-significant-liver-volume-reduction-in-phase-2b-trial-for-rare-polycystic-liver-disease 2025-06-18T20:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camurus-cam2029-shows-significant-liver-volume-reduction-in-phase-2b-trial-for-rare-polycystic-liver-disease 2025-06-18T20:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/tolremo-therapeutics-strengthens-leadership-with-key-appointments-as-tt125-802-shows-clinical-promise 2025-06-18T19:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tolremo-therapeutics-strengthens-leadership-with-key-appointments-as-tt125-802-shows-clinical-promise 2025-06-18T19:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/brightspring-s-onco360-pharmacy-selected-as-national-partner-for-three-new-cancer-and-rare-disease-therapies 2025-06-18T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brightspring-s-onco360-pharmacy-selected-as-national-partner-for-three-new-cancer-and-rare-disease-therapies 2025-06-18T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-qulipta-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-head-to-head-migraine-prevention-trial 2025-06-18T18:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-qulipta-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-head-to-head-migraine-prevention-trial 2025-06-18T18:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/singlera-genomics-gutseer-assay-achieves-81-5-sensitivity-in-detecting-early-stage-gastrointestinal-cancers 2025-06-18T18:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singlera-genomics-gutseer-assay-achieves-81-5-sensitivity-in-detecting-early-stage-gastrointestinal-cancers 2025-06-18T18:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-partners-with-msd-to-expand-distribution-of-diabetes-drug-portfolio-in-india 2025-06-18T16:58:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-partners-with-msd-to-expand-distribution-of-diabetes-drug-portfolio-in-india 2025-06-18T16:58:10+00:00 hourly 0.9 https://trial.medpath.com/news/nervgen-appoints-randall-kaye-as-chief-medical-advisor-following-positive-spinal-cord-injury-trial-results 2025-06-18T16:57:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nervgen-appoints-randall-kaye-as-chief-medical-advisor-following-positive-spinal-cord-injury-trial-results 2025-06-18T16:57:38+00:00 hourly 0.9 https://trial.medpath.com/news/curasight-advances-utreat-brain-cancer-therapy-with-phase-1-trial-submission-to-ema 2025-06-18T16:55:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curasight-advances-utreat-brain-cancer-therapy-with-phase-1-trial-submission-to-ema 2025-06-18T16:55:57+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-secures-india-patent-for-novel-spliceosome-inhibiting-adc-payload-technology 2025-06-18T16:55:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-therapeutics-secures-india-patent-for-novel-spliceosome-inhibiting-adc-payload-technology 2025-06-18T16:55:50+00:00 hourly 0.9 https://trial.medpath.com/news/respiratorius-secures-fda-pre-ind-meeting-for-val001-cancer-treatment-following-positive-physician-survey 2025-06-18T16:55:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/respiratorius-secures-fda-pre-ind-meeting-for-val001-cancer-treatment-following-positive-physician-survey 2025-06-18T16:55:44+00:00 hourly 0.9 https://trial.medpath.com/news/infinity-bio-secures-8m-series-a-to-advance-antibody-reactome-profiling-technology 2025-06-18T16:55:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infinity-bio-secures-8m-series-a-to-advance-antibody-reactome-profiling-technology 2025-06-18T16:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/climb-bio-strengthens-leadership-team-with-key-executive-appointments-to-advance-immune-mediated-disease-pipeline 2025-06-18T16:55:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/climb-bio-strengthens-leadership-team-with-key-executive-appointments-to-advance-immune-mediated-disease-pipeline 2025-06-18T16:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/pattern-computer-advances-ai-discovered-drug-for-multiple-hard-to-treat-cancers-to-testing-phase 2025-06-18T16:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pattern-computer-advances-ai-discovered-drug-for-multiple-hard-to-treat-cancers-to-testing-phase 2025-06-18T16:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/fareva-opens-new-gmp-sterile-pilot-unit-in-france-to-support-biotech-drug-manufacturing 2025-06-18T16:46:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fareva-opens-new-gmp-sterile-pilot-unit-in-france-to-support-biotech-drug-manufacturing 2025-06-18T16:46:20+00:00 hourly 0.9 https://trial.medpath.com/news/sandboxaq-releases-5-2-million-synthetic-molecules-dataset-to-accelerate-ai-driven-drug-discovery 2025-06-18T16:46:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandboxaq-releases-5-2-million-synthetic-molecules-dataset-to-accelerate-ai-driven-drug-discovery 2025-06-18T16:46:08+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-approves-over-the-counter-melatonin-and-prescription-psilocybin-for-treatment-resistant-depression 2025-06-18T16:44:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-approves-over-the-counter-melatonin-and-prescription-psilocybin-for-treatment-resistant-depression 2025-06-18T16:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/bavarian-nordic-sells-priority-review-voucher-for-160-million-following-chikungunya-vaccine-approval 2025-06-18T16:44:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bavarian-nordic-sells-priority-review-voucher-for-160-million-following-chikungunya-vaccine-approval 2025-06-18T16:44:40+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-advances-hemopurifier-cancer-trial-with-second-patient-treatment-in-australia 2025-06-18T16:44:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aethlon-medical-advances-hemopurifier-cancer-trial-with-second-patient-treatment-in-australia 2025-06-18T16:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/diagonal-therapeutics-diag723-shows-disease-modifying-potential-for-hereditary-hemorrhagic-telangiectasia-in-preclinical-studies 2025-06-18T16:42:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diagonal-therapeutics-diag723-shows-disease-modifying-potential-for-hereditary-hemorrhagic-telangiectasia-in-preclinical-studies 2025-06-18T16:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-pediatric-trial-for-moleculin-s-annamycin-in-acute-myeloid-leukemia 2025-06-18T16:41:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-expanded-pediatric-trial-for-moleculin-s-annamycin-in-acute-myeloid-leukemia 2025-06-18T16:41:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-integrated-sacral-neuromodulation-system-for-urinary-urge-incontinence 2025-06-18T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-integrated-sacral-neuromodulation-system-for-urinary-urge-incontinence 2025-06-18T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-expanded-dosing-and-pediatric-indication-for-firdapse-in-lambert-eaton-myasthenic-syndrome 2025-06-18T16:41:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-expanded-dosing-and-pediatric-indication-for-firdapse-in-lambert-eaton-myasthenic-syndrome 2025-06-18T16:41:04+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-study-identifies-three-b-cell-lymphoma-subgroups-with-distinct-cd19-car-t-response-patterns 2025-06-18T16:40:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-study-identifies-three-b-cell-lymphoma-subgroups-with-distinct-cd19-car-t-response-patterns 2025-06-18T16:40:53+00:00 hourly 0.9 https://trial.medpath.com/news/regeltec-initiates-u-s-pivotal-trial-for-hydrafil-system-in-chronic-low-back-pain-treatment 2025-06-18T16:40:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeltec-initiates-u-s-pivotal-trial-for-hydrafil-system-in-chronic-low-back-pain-treatment 2025-06-18T16:40:44+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-launches-phase-3-pediatric-trial-of-omaveloxolone-for-friedreich-ataxia 2025-06-18T15:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-launches-phase-3-pediatric-trial-of-omaveloxolone-for-friedreich-ataxia 2025-06-18T15:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-s-apitegromab-preserves-lean-muscle-mass-during-weight-loss-with-tirzepatide-in-phase-2-trial 2025-06-18T12:51:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-s-apitegromab-preserves-lean-muscle-mass-during-weight-loss-with-tirzepatide-in-phase-2-trial 2025-06-18T12:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/actio-biosciences-raises-66m-series-b-to-advance-rare-disease-programs-targeting-ion-channel-disorders 2025-06-18T12:51:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actio-biosciences-raises-66m-series-b-to-advance-rare-disease-programs-targeting-ion-channel-disorders 2025-06-18T12:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/aligos-therapeutics-strengthens-cmc-leadership-with-industry-veteran-ahead-of-phase-2-trial 2025-06-18T12:49:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aligos-therapeutics-strengthens-cmc-leadership-with-industry-veteran-ahead-of-phase-2-trial 2025-06-18T12:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-atogepant-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-phase-3-migraine-prevention-trial 2025-06-18T12:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-atogepant-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-phase-3-migraine-prevention-trial 2025-06-18T12:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/draig-therapeutics-emerges-from-stealth-with-140m-to-advance-novel-neuropsychiatric-therapies 2025-06-18T12:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/draig-therapeutics-emerges-from-stealth-with-140m-to-advance-novel-neuropsychiatric-therapies 2025-06-18T12:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-partners-with-phnyx-lab-to-deploy-ai-powered-drug-development-platform 2025-06-18T11:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-partners-with-phnyx-lab-to-deploy-ai-powered-drug-development-platform 2025-06-18T11:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/senate-republicans-drop-orphan-drug-exemptions-from-trump-tax-bill-dealing-blow-to-rare-disease-drug-development 2025-06-18T09:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-republicans-drop-orphan-drug-exemptions-from-trump-tax-bill-dealing-blow-to-rare-disease-drug-development 2025-06-18T09:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-tzield-debuts-in-china-as-first-fda-approved-therapy-to-delay-type-1-diabetes-onset 2025-06-18T09:05:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-tzield-debuts-in-china-as-first-fda-approved-therapy-to-delay-type-1-diabetes-onset 2025-06-18T09:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/inoviq-s-car-exosome-therapy-achieves-88-cancer-cell-kill-rate-in-preclinical-study 2025-06-18T09:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inoviq-s-car-exosome-therapy-achieves-88-cancer-cell-kill-rate-in-preclinical-study 2025-06-18T09:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/mercalis-and-pharmacord-merge-to-form-valeris-creating-integrated-therapy-commercialization-platform 2025-06-18T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mercalis-and-pharmacord-merge-to-form-valeris-creating-integrated-therapy-commercialization-platform 2025-06-18T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-and-msn-settle-entresto-patent-dispute-boosting-divi-s-laboratories-outlook 2025-06-18T09:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-and-msn-settle-entresto-patent-dispute-boosting-divi-s-laboratories-outlook 2025-06-18T09:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-simultaneous-whole-exome-and-transcriptome-cancer-test-for-precision-oncology 2025-06-18T09:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-simultaneous-whole-exome-and-transcriptome-cancer-test-for-precision-oncology 2025-06-18T09:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/nec-and-chugai-pharmaceutical-develop-ai-system-to-accelerate-cancer-drug-combination-discovery 2025-06-18T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nec-and-chugai-pharmaceutical-develop-ai-system-to-accelerate-cancer-drug-combination-discovery 2025-06-18T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/expanding-innovations-receives-fda-clearance-for-n-gage-lumbar-plate-system 2025-06-18T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expanding-innovations-receives-fda-clearance-for-n-gage-lumbar-plate-system 2025-06-18T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-announces-leadership-transition-as-ceo-dr-james-hayward-retires-after-20-year-tenure 2025-06-18T06:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-dna-sciences-announces-leadership-transition-as-ceo-dr-james-hayward-retires-after-20-year-tenure 2025-06-18T06:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-pharma-receives-five-fda-observations-at-north-carolina-facility-no-data-integrity-issues-found 2025-06-18T06:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-pharma-receives-five-fda-observations-at-north-carolina-facility-no-data-integrity-issues-found 2025-06-18T06:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/saverone-receives-us-patent-for-advanced-sensor-fusion-technology-to-combat-driver-distraction 2025-06-18T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saverone-receives-us-patent-for-advanced-sensor-fusion-technology-to-combat-driver-distraction 2025-06-18T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/blue-biofuels-secures-seventh-u-s-patent-for-cellulose-to-sugar-technology 2025-06-18T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blue-biofuels-secures-seventh-u-s-patent-for-cellulose-to-sugar-technology 2025-06-18T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/medibank-partners-with-emyria-to-fund-innovative-ptsd-treatment-program-in-australian-healthcare-first 2025-06-18T05:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medibank-partners-with-emyria-to-fund-innovative-ptsd-treatment-program-in-australian-healthcare-first 2025-06-18T05:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/occam-immune-and-cancer-research-institute-form-strategic-partnership-to-advance-personalized-immunotherapy 2025-06-18T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/occam-immune-and-cancer-research-institute-form-strategic-partnership-to-advance-personalized-immunotherapy 2025-06-18T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-stedim-biotech-completes-major-manufacturing-expansion-in-france-to-meet-growing-bioprocessing-demand 2025-06-18T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sartorius-stedim-biotech-completes-major-manufacturing-expansion-in-france-to-meet-growing-bioprocessing-demand 2025-06-18T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/relmada-therapeutics-strengthens-ndv-01-bladder-cancer-program-with-key-leadership-appointments-ahead-of-phase-3-trial 2025-06-18T02:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relmada-therapeutics-strengthens-ndv-01-bladder-cancer-program-with-key-leadership-appointments-ahead-of-phase-3-trial 2025-06-18T02:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/castle-biosciences-and-scibase-partner-to-develop-ai-powered-atopic-dermatitis-flare-prediction-test 2025-06-18T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/castle-biosciences-and-scibase-partner-to-develop-ai-powered-atopic-dermatitis-flare-prediction-test 2025-06-18T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/medtech-products-recalls-little-remedies-honey-cough-syrup-nationwide-due-to-bacterial-contamination 2025-06-18T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtech-products-recalls-little-remedies-honey-cough-syrup-nationwide-due-to-bacterial-contamination 2025-06-18T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-receives-23-7-million-arpa-h-grant-to-map-immunotherapy-resistance-in-lung-cancer 2025-06-18T00:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-receives-23-7-million-arpa-h-grant-to-map-immunotherapy-resistance-in-lung-cancer 2025-06-18T00:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/incannex-healthcare-forms-joint-venture-with-mind-medicine-australia-to-launch-psychedelic-therapy-clinic-in-melbourne 2025-06-18T00:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incannex-healthcare-forms-joint-venture-with-mind-medicine-australia-to-launch-psychedelic-therapy-clinic-in-melbourne 2025-06-18T00:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/nmdp-access-trial-shows-mismatched-donors-expand-stem-cell-transplant-access-for-blood-cancer-patients 2025-06-18T00:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nmdp-access-trial-shows-mismatched-donors-expand-stem-cell-transplant-access-for-blood-cancer-patients 2025-06-18T00:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-research-foundation-and-boehringer-ingelheim-launch-2-25-million-initiative-to-target-her2-mutant-lung-cancer 2025-06-18T00:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-cancer-research-foundation-and-boehringer-ingelheim-launch-2-25-million-initiative-to-target-her2-mutant-lung-cancer 2025-06-18T00:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/microbot-medical-secures-china-patent-for-liberty-robotic-system-ahead-of-q3-2025-us-launch 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbot-medical-secures-china-patent-for-liberty-robotic-system-ahead-of-q3-2025-us-launch 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/three-minute-eeg-test-shows-promise-for-early-alzheimer-s-detection-in-clinical-trial 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-minute-eeg-test-shows-promise-for-early-alzheimer-s-detection-in-clinical-trial 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tislelizumab-shows-promise-as-adjuvant-therapy-for-high-risk-hepatocellular-carcinoma-patients 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tislelizumab-shows-promise-as-adjuvant-therapy-for-high-risk-hepatocellular-carcinoma-patients 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-cfo-resigns-amid-amtagvi-launch-struggles-and-securities-fraud-investigation 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-cfo-resigns-amid-amtagvi-launch-struggles-and-securities-fraud-investigation 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/earlyhealth-group-acquires-turkish-pharmaceutical-distributor-corena-in-100m-life-sciences-expansion 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/earlyhealth-group-acquires-turkish-pharmaceutical-distributor-corena-in-100m-life-sciences-expansion 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mitochondrial-biomarkers-identified-for-atrial-fibrillation-through-integrated-bioinformatics-analysis 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mitochondrial-biomarkers-identified-for-atrial-fibrillation-through-integrated-bioinformatics-analysis 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-georgia-develops-first-broad-spectrum-fungal-vaccine-enters-clinical-trials 2025-06-17T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-georgia-develops-first-broad-spectrum-fungal-vaccine-enters-clinical-trials 2025-06-17T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/canada-outpaces-oecd-countries-in-new-medicine-launches-despite-rising-treatment-costs 2025-06-17T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-outpaces-oecd-countries-in-new-medicine-launches-despite-rising-treatment-costs 2025-06-17T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/bioaegis-therapeutics-receives-fda-fast-track-designation-for-novel-ards-treatment 2025-06-17T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioaegis-therapeutics-receives-fda-fast-track-designation-for-novel-ards-treatment 2025-06-17T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/exceptional-responders-14-pancreatic-cancer-patients-show-remarkable-immunotherapy-outcomes-in-multi-institutional-study 2025-06-17T21:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exceptional-responders-14-pancreatic-cancer-patients-show-remarkable-immunotherapy-outcomes-in-multi-institutional-study 2025-06-17T21:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/celltrio-secures-15-million-to-accelerate-global-expansion-of-cell-therapy-automation-platform 2025-06-17T21:04:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrio-secures-15-million-to-accelerate-global-expansion-of-cell-therapy-automation-platform 2025-06-17T21:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/bioage-labs-partners-with-norwegian-biobank-to-accelerate-aging-related-drug-discovery 2025-06-17T21:01:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioage-labs-partners-with-norwegian-biobank-to-accelerate-aging-related-drug-discovery 2025-06-17T21:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/skyhawk-therapeutics-initiates-phase-2-3-trial-of-sky-0515-for-huntington-s-disease 2025-06-17T20:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skyhawk-therapeutics-initiates-phase-2-3-trial-of-sky-0515-for-huntington-s-disease 2025-06-17T20:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/ashvattha-therapeutics-unveils-novel-nanomedicine-radiotracers-for-neuroinflammation-and-cancer-imaging-at-snmmi-2025 2025-06-17T20:15:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ashvattha-therapeutics-unveils-novel-nanomedicine-radiotracers-for-neuroinflammation-and-cancer-imaging-at-snmmi-2025 2025-06-17T20:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/visby-medical-secures-65-million-to-launch-fda-authorized-at-home-sti-test 2025-06-17T20:15:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/visby-medical-secures-65-million-to-launch-fda-authorized-at-home-sti-test 2025-06-17T20:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/pelage-pharmaceuticals-pp405-shows-hair-regeneration-potential-in-phase-2a-trial 2025-06-17T20:11:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelage-pharmaceuticals-pp405-shows-hair-regeneration-potential-in-phase-2a-trial 2025-06-17T20:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-launches-in-florida-to-test-investigational-oral-medication-for-severe-thunderstorm-aversion-in-dogs 2025-06-17T19:11:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-launches-in-florida-to-test-investigational-oral-medication-for-severe-thunderstorm-aversion-in-dogs 2025-06-17T19:11:09+00:00 hourly 0.9 https://trial.medpath.com/news/quilt-health-secures-6m-seed-funding-to-modernize-clinical-trial-access-for-complex-diseases 2025-06-17T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quilt-health-secures-6m-seed-funding-to-modernize-clinical-trial-access-for-complex-diseases 2025-06-17T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/nature-study-validates-non-invasive-fat-reduction-technology-for-abdominal-obesity-treatment 2025-06-17T18:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-study-validates-non-invasive-fat-reduction-technology-for-abdominal-obesity-treatment 2025-06-17T18:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/maxion-therapeutics-strengthens-leadership-with-appointment-of-dr-stefan-hartle-as-chief-development-officer 2025-06-17T18:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxion-therapeutics-strengthens-leadership-with-appointment-of-dr-stefan-hartle-as-chief-development-officer 2025-06-17T18:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/heart-drug-cilostazol-shows-promise-for-treating-growth-disorders-in-preclinical-study 2025-06-17T18:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heart-drug-cilostazol-shows-promise-for-treating-growth-disorders-in-preclinical-study 2025-06-17T18:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/mark-cuban-cost-plus-drug-company-expands-affordable-healthcare-access-through-strategic-partnerships 2025-06-17T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mark-cuban-cost-plus-drug-company-expands-affordable-healthcare-access-through-strategic-partnerships 2025-06-17T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulator-reports-111-deaths-potentially-linked-to-glp-1-weight-loss-medications 2025-06-17T16:56:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-regulator-reports-111-deaths-potentially-linked-to-glp-1-weight-loss-medications 2025-06-17T16:56:27+00:00 hourly 0.9 https://trial.medpath.com/news/avata-biosciences-secures-95m-partnership-with-oceanus-bio-for-novel-cbd-therapies-in-asian-markets 2025-06-17T16:55:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avata-biosciences-secures-95m-partnership-with-oceanus-bio-for-novel-cbd-therapies-in-asian-markets 2025-06-17T16:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/aragen-to-launch-gmp-biologics-manufacturing-in-india-with-advanced-fed-batch-platform 2025-06-17T16:55:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aragen-to-launch-gmp-biologics-manufacturing-in-india-with-advanced-fed-batch-platform 2025-06-17T16:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/llusern-scientific-achieves-iso-13485-certification-for-rapid-uti-diagnostic-system 2025-06-17T16:55:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/llusern-scientific-achieves-iso-13485-certification-for-rapid-uti-diagnostic-system 2025-06-17T16:55:24+00:00 hourly 0.9 https://trial.medpath.com/news/sunrock-biopharma-and-escugen-partner-to-develop-first-in-class-ccr9-targeted-adc-for-solid-tumors 2025-06-17T16:51:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunrock-biopharma-and-escugen-partner-to-develop-first-in-class-ccr9-targeted-adc-for-solid-tumors 2025-06-17T16:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-partners-with-noetik-to-develop-ai-powered-biomarkers-for-precision-immunotherapy 2025-06-17T16:50:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agenus-partners-with-noetik-to-develop-ai-powered-biomarkers-for-precision-immunotherapy 2025-06-17T16:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/hanchorbio-s-hcb101-checkpoint-inhibitor-shows-promising-safety-and-efficacy-balance-in-phase-1b-trial 2025-06-17T16:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanchorbio-s-hcb101-checkpoint-inhibitor-shows-promising-safety-and-efficacy-balance-in-phase-1b-trial 2025-06-17T16:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-secures-452-5m-licensing-deal-for-gastroparesis-drug-pcs12852 2025-06-17T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/processa-pharmaceuticals-secures-452-5m-licensing-deal-for-gastroparesis-drug-pcs12852 2025-06-17T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-medicovestor-s-first-in-class-adc-for-pancreatic-cancer 2025-06-17T16:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-medicovestor-s-first-in-class-adc-for-pancreatic-cancer 2025-06-17T16:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/astrocyte-pharmaceuticals-initiates-phase-2-trial-for-first-in-class-concussion-drug-ast-004 2025-06-17T16:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrocyte-pharmaceuticals-initiates-phase-2-trial-for-first-in-class-concussion-drug-ast-004 2025-06-17T16:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/tharimmune-appoints-new-ceo-and-board-members-to-advance-opioid-antagonist-th104-development 2025-06-17T16:19:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tharimmune-appoints-new-ceo-and-board-members-to-advance-opioid-antagonist-th104-development 2025-06-17T16:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/lipella-pharmaceuticals-secures-patent-for-mri-based-diagnostic-technology-to-detect-interstitial-cystitis 2025-06-17T16:18:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipella-pharmaceuticals-secures-patent-for-mri-based-diagnostic-technology-to-detect-interstitial-cystitis 2025-06-17T16:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-proposes-elimination-of-phase-iii-clinical-trials-for-biosimilar-approvals 2025-06-17T16:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-proposes-elimination-of-phase-iii-clinical-trials-for-biosimilar-approvals 2025-06-17T16:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/phoenix-study-launches-world-s-largest-pharmacogenomics-trial-to-personalize-drug-prescribing-in-scotland 2025-06-17T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phoenix-study-launches-world-s-largest-pharmacogenomics-trial-to-personalize-drug-prescribing-in-scotland 2025-06-17T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-s-jyong-biotech-raises-20m-in-nasdaq-ipo-to-advance-botanical-urinary-disease-treatments 2025-06-17T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-s-jyong-biotech-raises-20m-in-nasdaq-ipo-to-advance-botanical-urinary-disease-treatments 2025-06-17T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/china-proposes-30-day-review-pathway-for-innovative-drug-clinical-trials-nationwide 2025-06-17T14:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-proposes-30-day-review-pathway-for-innovative-drug-clinical-trials-nationwide 2025-06-17T14:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/prometheus-laboratories-expands-precision-guided-dosing-platform-with-new-tests-for-ibd-biologics 2025-06-17T14:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prometheus-laboratories-expands-precision-guided-dosing-platform-with-new-tests-for-ibd-biologics 2025-06-17T14:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-pharmaceuticals-completes-enrollment-in-phase-3-trial-for-central-precocious-puberty-treatment 2025-06-17T13:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-completes-enrollment-in-phase-3-trial-for-central-precocious-puberty-treatment 2025-06-17T13:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/tisento-therapeutics-receives-fda-fast-track-designation-for-zagociguat-in-melas-treatment 2025-06-17T13:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tisento-therapeutics-receives-fda-fast-track-designation-for-zagociguat-in-melas-treatment 2025-06-17T13:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/qureight-s-ai-powered-synthetic-control-arms-validate-efficacy-of-avalyn-s-inhaled-pirfenidone-for-rare-lung-disease 2025-06-17T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qureight-s-ai-powered-synthetic-control-arms-validate-efficacy-of-avalyn-s-inhaled-pirfenidone-for-rare-lung-disease 2025-06-17T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-launches-eur50-million-corporate-bond-to-accelerate-biosimilar-portfolio-development 2025-06-17T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-launches-eur50-million-corporate-bond-to-accelerate-biosimilar-portfolio-development 2025-06-17T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/basf-opens-new-gmp-solution-center-in-michigan-to-strengthen-biopharma-manufacturing-capabilities 2025-06-17T13:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basf-opens-new-gmp-solution-center-in-michigan-to-strengthen-biopharma-manufacturing-capabilities 2025-06-17T13:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/isomorphic-labs-appoints-dr-ben-wolf-as-chief-medical-officer-establishes-us-operations 2025-06-17T12:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isomorphic-labs-appoints-dr-ben-wolf-as-chief-medical-officer-establishes-us-operations 2025-06-17T12:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-researchers-develop-car-t-therapy-for-aggressive-bladder-cancer-variant-using-novel-biomarkers 2025-06-17T12:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-researchers-develop-car-t-therapy-for-aggressive-bladder-cancer-variant-using-novel-biomarkers 2025-06-17T12:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-and-parkinson-s-charities-launch-drug-repurposing-partnership-to-accelerate-treatment-development 2025-06-17T12:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-and-parkinson-s-charities-launch-drug-repurposing-partnership-to-accelerate-treatment-development 2025-06-17T12:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/vsa-announces-acquisition-of-ai-clinical-development-company-hopeai-to-transform-drug-development-timelines 2025-06-17T12:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vsa-announces-acquisition-of-ai-clinical-development-company-hopeai-to-transform-drug-development-timelines 2025-06-17T12:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/nodthera-appoints-former-astrazeneca-executive-elisabeth-bjork-to-board-as-phase-2-obesity-trial-advances 2025-06-17T12:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nodthera-appoints-former-astrazeneca-executive-elisabeth-bjork-to-board-as-phase-2-obesity-trial-advances 2025-06-17T12:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-gene-editing-biotech-verve-therapeutics-for-1-3-billion-to-expand-cholesterol-treatment-pipeline 2025-06-17T10:59:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-acquires-gene-editing-biotech-verve-therapeutics-for-1-3-billion-to-expand-cholesterol-treatment-pipeline 2025-06-17T10:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/china-patent-office-upholds-harbour-biomed-s-heavy-chain-antibody-patent-in-legal-victory-over-biocytogen 2025-06-17T10:58:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-patent-office-upholds-harbour-biomed-s-heavy-chain-antibody-patent-in-legal-victory-over-biocytogen 2025-06-17T10:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/angle-advances-liquid-biopsy-technology-with-dual-dna-analysis-and-androgen-receptor-profiling-at-eacr-2025 2025-06-17T10:58:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angle-advances-liquid-biopsy-technology-with-dual-dna-analysis-and-androgen-receptor-profiling-at-eacr-2025 2025-06-17T10:58:21+00:00 hourly 0.9 https://trial.medpath.com/news/orion-and-glykos-extend-adc-partnership-to-develop-six-next-generation-cancer-therapies 2025-06-17T09:13:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orion-and-glykos-extend-adc-partnership-to-develop-six-next-generation-cancer-therapies 2025-06-17T09:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/simvastatin-fails-to-show-antidepressant-benefits-in-major-depression-and-obesity-trial 2025-06-17T09:13:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simvastatin-fails-to-show-antidepressant-benefits-in-major-depression-and-obesity-trial 2025-06-17T09:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-proposes-streamlined-30-day-review-channel-for-category-1-innovative-drugs 2025-06-17T09:12:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-proposes-streamlined-30-day-review-channel-for-category-1-innovative-drugs 2025-06-17T09:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/hera-biotech-acquires-herafem-point-of-care-cervical-cancer-diagnostic-with-91-sensitivity 2025-06-17T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hera-biotech-acquires-herafem-point-of-care-cervical-cancer-diagnostic-with-91-sensitivity 2025-06-17T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/smartlabs-and-iwg-form-10-year-partnership-to-expand-global-lab-infrastructure-access 2025-06-17T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartlabs-and-iwg-form-10-year-partnership-to-expand-global-lab-infrastructure-access 2025-06-17T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/everzom-secures-eur3-million-france-2030-funding-to-scale-exosome-bioproduction-for-crohn-s-disease-treatment 2025-06-17T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everzom-secures-eur3-million-france-2030-funding-to-scale-exosome-bioproduction-for-crohn-s-disease-treatment 2025-06-17T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-submits-fda-application-for-next-generation-lungfit-ph-ii-nitric-oxide-system 2025-06-17T05:00:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-air-submits-fda-application-for-next-generation-lungfit-ph-ii-nitric-oxide-system 2025-06-17T05:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/clarity-pharmaceuticals-secures-major-manufacturing-deal-to-scale-cu-sar-bispsma-production-for-prostate-cancer-diagnostics 2025-06-17T05:00:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clarity-pharmaceuticals-secures-major-manufacturing-deal-to-scale-cu-sar-bispsma-production-for-prostate-cancer-diagnostics 2025-06-17T05:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/biomx-achieves-breakthrough-in-phage-therapy-with-positive-phase-2-results-for-antibiotic-resistant-infections 2025-06-17T05:00:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomx-achieves-breakthrough-in-phage-therapy-with-positive-phase-2-results-for-antibiotic-resistant-infections 2025-06-17T05:00:43+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-abbott-s-rapid-whole-blood-test-for-concussion-assessment 2025-06-17T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-abbott-s-rapid-whole-blood-test-for-concussion-assessment 2025-06-17T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-activity-plummets-20-as-funding-crisis-grips-biotech-sector 2025-06-17T03:03:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-activity-plummets-20-as-funding-crisis-grips-biotech-sector 2025-06-17T03:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/thyroid-cancer-pipeline-shows-robust-growth-with-50-companies-developing-novel-therapies 2025-06-17T02:03:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thyroid-cancer-pipeline-shows-robust-growth-with-50-companies-developing-novel-therapies 2025-06-17T02:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-pharma-secures-7-4-billion-opioid-settlement-support-from-55-states-and-territories 2025-06-17T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-pharma-secures-7-4-billion-opioid-settlement-support-from-55-states-and-territories 2025-06-17T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-csl-s-andembry-for-hereditary-angioedema-prevention-with-novel-factor-xiia-targeting 2025-06-17T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-csl-s-andembry-for-hereditary-angioedema-prevention-with-novel-factor-xiia-targeting 2025-06-17T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-s-leqembi-shows-accelerating-growth-with-58-global-sales-increase-despite-slow-market-adoption 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-s-leqembi-shows-accelerating-growth-with-58-global-sales-increase-despite-slow-market-adoption 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/trust-trial-shows-primary-surgery-improves-progression-free-survival-in-advanced-ovarian-cancer-despite-missing-overall-survival-endpoint 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trust-trial-shows-primary-surgery-improves-progression-free-survival-in-advanced-ovarian-cancer-despite-missing-overall-survival-endpoint 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-second-complete-response-letter-for-odronextamab-in-relapsed-refractory-follicular-lymphoma 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-second-complete-response-letter-for-odronextamab-in-relapsed-refractory-follicular-lymphoma 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/digital-inhaler-technology-shows-promise-for-early-copd-exacerbation-detection 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-inhaler-technology-shows-promise-for-early-copd-exacerbation-detection 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-detects-early-liver-transplant-rejection-using-cell-free-dna-analysis 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-detects-early-liver-transplant-rejection-using-cell-free-dna-analysis 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/mabion-and-novalgen-partner-to-advance-novel-t-cell-engager-nvg-222-for-cancer-treatment 2025-06-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabion-and-novalgen-partner-to-advance-novel-t-cell-engager-nvg-222-for-cancer-treatment 2025-06-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/enzene-expands-new-jersey-biomanufacturing-facility-by-26000-square-feet-ahead-of-opening 2025-06-16T23:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enzene-expands-new-jersey-biomanufacturing-facility-by-26000-square-feet-ahead-of-opening 2025-06-16T23:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/edx-medical-partners-with-spire-healthcare-to-advance-diagnostic-innovation-for-cancer-and-cardiovascular-disease 2025-06-16T23:04:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edx-medical-partners-with-spire-healthcare-to-advance-diagnostic-innovation-for-cancer-and-cardiovascular-disease 2025-06-16T23:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/help-therapeutics-partners-with-china-resources-sanjiu-to-advance-ipsc-derived-heart-failure-therapy-hicm-188 2025-06-16T23:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/help-therapeutics-partners-with-china-resources-sanjiu-to-advance-ipsc-derived-heart-failure-therapy-hicm-188 2025-06-16T23:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/cresilon-expands-vetigel-distribution-to-canadian-veterinary-market-through-mccarthy-vet-partnership 2025-06-16T22:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cresilon-expands-vetigel-distribution-to-canadian-veterinary-market-through-mccarthy-vet-partnership 2025-06-16T22:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-reports-complete-response-in-advanced-nsclc-patient-after-failed-standard-therapies 2025-06-16T22:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-reports-complete-response-in-advanced-nsclc-patient-after-failed-standard-therapies 2025-06-16T22:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/shasqi-achieves-first-in-human-success-with-click-chemistry-cancer-therapy-delivering-12-fold-higher-doxorubicin-doses 2025-06-16T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shasqi-achieves-first-in-human-success-with-click-chemistry-cancer-therapy-delivering-12-fold-higher-doxorubicin-doses 2025-06-16T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-receives-ema-approval-to-skip-phase-1-2-trials-for-mpox-vaccine-accelerating-path-to-market 2025-06-16T21:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-receives-ema-approval-to-skip-phase-1-2-trials-for-mpox-vaccine-accelerating-path-to-market 2025-06-16T21:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-surovatamig-shows-promise-as-next-generation-bite-therapy-for-relapsed-refractory-b-all 2025-06-16T21:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-surovatamig-shows-promise-as-next-generation-bite-therapy-for-relapsed-refractory-b-all 2025-06-16T21:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/patent-extensions-drive-200-billion-in-excess-u-s-drug-spending-i-mak-analysis-reveals 2025-06-16T21:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patent-extensions-drive-200-billion-in-excess-u-s-drug-spending-i-mak-analysis-reveals 2025-06-16T21:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/clarametyx-s-cmtx-101-shows-promise-in-cystic-fibrosis-infection-trial-advances-to-next-phase 2025-06-16T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clarametyx-s-cmtx-101-shows-promise-in-cystic-fibrosis-infection-trial-advances-to-next-phase 2025-06-16T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/eolo-pharma-s-sana-demonstrates-novel-energy-burning-mechanism-for-obesity-treatment-in-first-in-human-study 2025-06-16T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eolo-pharma-s-sana-demonstrates-novel-energy-burning-mechanism-for-obesity-treatment-in-first-in-human-study 2025-06-16T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-cdmo-cro-services-can-reduce-drug-development-timelines-by-nearly-three-years-tufts-study-finds 2025-06-16T21:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-cdmo-cro-services-can-reduce-drug-development-timelines-by-nearly-three-years-tufts-study-finds 2025-06-16T21:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/asc2escalate-trial-shows-promising-results-for-asciminib-in-second-line-cml-treatment 2025-06-16T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asc2escalate-trial-shows-promising-results-for-asciminib-in-second-line-cml-treatment 2025-06-16T20:06:50+00:00 hourly 0.9